Pharmaron（300759）

市场: A股日期: 2026-07-15评级: Investment Recommendation: Buy. Target Price: 42.0 CNY. Basis for Decision: Bullish evidence overwhelms bearish evidence overall: surge in new orders (year-over-year growth rate exceeds 30%), net profit attributable to parent company returned to positive growth, strong technical trend not reversed. Sell and Hold options were rejected. Enter with a light base position (2%) plus moving average discipline, dynamic stop-loss to control risk, avoid the dilemma of missing out or chasing highs.风险: Medium置信度: 0.7

market_report

# **Pharmaron (300759) Technical Analysis Report** **Analysis Date: 7 15, 2026** --- ## I. Basic Stock Information - **Company Name**: Pharmaron - **Ticker**: 300759 - **Market**: China A-Shares - **Current Price**: ¥40.30 — 7/15/2026 15:00 Beijing Time (UTC+8, Close) - **Change**: +2.85 (+8.36%) - **Trading Volume**: 4,475,142 shares --- ## II. Technical Indicator Analysis ### 1. Trend Environment Assessment (ADX) ADX value is 53.49, above 40, indicating a **strong trend market**. In a strong trend environment, trend-following strategies take precedence over range-bound strategies, and the reliability of extreme signals from oscillators (such as RSI and Bollinger Band position) declines. +DI (33.98) is well above -DI (6.49), showing that bullish forces hold an absolute dominant position. ### 2. Moving Average (MA) Analysis The current moving average system shows a classic **bullish alignment**: MA5 (33.25), MA10 (31.63), MA20 (28.24), and MA60 (26.21) are diverging upward in sequence, and the closing price 40.30 is well above all moving averages. This alignment is a strong signal of an ongoing uptrend. The price deviation from MA5 is large (approximately 21%), suggesting short-term technical correction pressure; however, in a strong trend, prices often correct through sideways consolidation rather than sharp declines. ### 3. MACD Indicator Analysis MACD is in a **clear bullish state**: DIF (2.595) is above DEA (1.726), and the MACD histogram value is 1.739, positive. Both DIF and DEA are above the zero line, a classic bullish pattern. Attention should be paid to whether the MACD histogram value begins to shrink, which could be an early sign of weakening upward momentum. However, in a strong trend, the effectiveness of MACD is higher than that of oscillators; the current signal remains bullish. ### 4. RSI Relative Strength Index RSI6 is 93.61, RSI12 is 88.31, and RSI24 is 82.04; all three indicators are in **severe overbought territory** (>80). However, based on the ADX (53.49>40), the current market is in a strong trend environment, and **RSI overbought does not constitute a direct sell signal**. In a strong trend, the RSI can remain in overbought territory for an extended period. Still, the RSI values are approaching extreme levels, suggesting that the risk-reward for chasing highs in the short term has deteriorated, and heavy positions in buying should be avoided. ### 5. Bollinger Bands (BOLL) Analysis The current price is above the upper Bollinger Band (36.74) (price position 101.1%), indicating an **extremely strong condition**. The Bollinger Band channel has expanded significantly, with the gap between the upper and lower bands widening, showing that volatility is increasing. In a strong trend, prices can operate near or above the upper band for a long time, but a breakout above the upper band usually implies short-term sentiment overheating and a technical need to revert toward the middle band. ### 6. Volume-Price Analysis (MFI + OBV) **MFI (Money Flow Index)**: The current value is 89.66, deep in **overbought territory** (>80). This indicates that capital inflows have been highly concentrated and market sentiment is exuberant. MFI and price are rising in sync, suggesting that the rally has capital support and is not a hollow advance. However, MFI is near extreme levels, and whether follow-up capital can sustain will be a key factor determining the continuation of the trend. **OBV (On-Balance Volume)**: The 5-day moving average of OBV is trending upward, in line with price, with **no clear divergence**. Volume and price are well-coordinated, with the rally supported by trading volume. In summary: MFI and OBV are rising together, volume-price relationships are healthy, but MFI near extremes suggests that capital heat has reached a high level, warranting caution against short-term volatility from profit-taking. ### 8(8). Volatility Analysis (ATR) ATR (14) is 2.48 CNY, with an average daily volatility of approximately 6.7%, considered **moderately high volatility**. Recent price fluctuations have intensified, consistent with the expansion of the Bollinger Band channel. For traders, it is recommended to set stop-losses based on 1.5-2 times ATR, i.e., approximately 3.7-5.0 CNY. Conservative investors may place stops near MA20 (28.24) or MA60 (26.21), but given the large deviation between current price and moving averages, practical effective stops could be based on recent lows or key support levels. --- ## III. Price Trend Analysis ### 1. Short-Term Trend The daily timeframe shows a **strongly rising trend**. Prices have successively broken through prior highs, the moving average system is in a bullish alignment with upward divergence, and MACD and RSI both point to bullishness. Short-term momentum is very strong, but RSI and MFI are at extreme overbought levels, suggesting the possibility of a technical adjustment or sideways consolidation to digest profit-taking in the short term. Adjustments in a strong trend are typically mild. ### 2. Medium-Term Trend MA20 (28.24) and MA60 (26.21) are steadily rising, and the price is well above these moving averages, indicating a **clear and healthy** medium-term uptrend. Based on the slope of the moving averages, the MA20 is steepening, showing that medium-term bullish power is strengthening. As long as the 20-day moving average does not turn downward, the medium-term trend remains bullish. ### 3. Volume Analysis The most recent trading day volume was 4,475,142 shares, significantly higher than the previous 5-day average volume (895,028 shares), **price and volume rising together**. Volume expanded markedly during the breakout rally, indicating increased market participation and active bullish capital inflow. Attention should be paid to whether volume can maintain this expansion level in subsequent trading days; if price rises while volume shrinks (divergence), it would be a warning signal of weakening upward momentum. ### 4. Multi-Timeframe Verification With only daily data available, we infer weekly status based on daily data: the current daily closing price (40.30) is well above MA60 (26.21); if measured by weekly moving averages (e.g., weekly MA10, weekly MA20), it is likely still in a bullish alignment. Daily-level technical indicators are fully overbought, but weekly-level trends tend to have greater inertia. **Multi-timeframe convergence** assessment: - **Daily**: Extremely strong in the short term, severely overbought, may require technical correction; - **Weekly (inferred)**: Uptrend intact, healthy bullish pattern, no top signal; - **Conclusion**: Medium- to long-term trend is upward; short-term overbought does not change the medium-term outlook. Investors should avoid selling against the trend due to daily overbought conditions but may wait for short-term pullbacks or consolidation to find more favorable entry points for adding positions. --- ## IV. Investment Recommendations ### 1. Framework Assessment The current market is in a **strong trend framework** (ADX=53.49>40). Within this framework, a trend-following mindset should prevail, and overbought signals should not be used as bearish rationale. Trend-following strategies outperform counter-trend strategies. ### 2. Trading Suggestions - **Holders**: Can continue to hold, but should tighten take-profit levels or set protective stop-losses (e.g., raise stop to just below the recent uptrend line or near MA5). Adding positions during extreme overbought conditions is not recommended. - **Non-holders**: Chasing at current levels carries high risk. It is advisable to wait for a pullback to near MA5 (33.25) or look for entry opportunities within a consolidation range. The first pullback toward MA10 (31.63) in a strong trend often provides a good dip-buying opportunity. - **Risk Management**: Given the large short-term gains and severely overbought indicators, single position size should be controlled, and heavy chasing should be avoided. ### 3. Key Levels - **Key Support**: First support – MA5 (33.25), Second support – MA10 (31.63), Third support – MA20 (28.24). - **Key Resistance**: The recent high area. Since prices have broken above prior highs, there is no clear historical resistance above; attention can be paid to psychological resistance at round numbers (e.g., 45 CNY, 50 CNY). - **Stop-Loss Reference**: Aggressive stops can be placed below MA5 (33.25); conservative stops below MA10 (31.63), or set at approximately 37.8 CNY based on ATR (2.48) (closing price minus 1.5 times ATR). - **Reversal Warning Signals**: Including but not limited to: a single-day heavy-volume long bearish candle engulfing multiple days of gains, ADX declining from a high with +DI flattening or falling, price breaking below MA20 (28.24), or a high-level MACD death cross. Until such signals appear, maintain a bullish bias. --- *Disclaimer: This report is generated based on public data as of the close on 7 15, 2026. It is for technical analysis reference only and does not constitute any investment advice. Stock market investing involves risk; trade with caution and make decisions based on fundamentals and your own risk tolerance.*

news_report

Alright, as a professional financial news analyst, I will conduct a detailed news impact analysis on stock 300759 (Pharmaron) based on the latest news data you provided up to 7/15/2026 at 19:00. --- ### **Pharmaron (300759) In-Depth News Analysis Report** #### **1. Summary of News Events** This analysis covers 10 news articles about Pharmaron, mainly concentrated from **7/13/2026 to 7/15/2026**, with extremely high timeliness, all within 48 hours. All news sentiments are marked as "**positive**", indicating positive market sentiment. **Core Event Chain:** - **Earnings Forecast Release (Evening of 7/13/2026):** This was the fundamental driving event for this round. Pharmaron released its 2026 H1 earnings forecast. Key data as follows: - **Net profit attributable to parent:** Expected CNY 7.29 hundred million - CNY 7.72 hundred million, YoY growth **4% - 10%**. - **Revenue:** Expected CNY 74.72 hundred million - CNY 76.65 hundred million, YoY growth **16% - 19%**. - **Newly signed orders:** YoY growth over **30%**, among which small molecule CDMO services new orders YoY growth over **50%**. - **Sector Momentum and Individual Stock Surge (7/14/2026 - 7/15/2026):** Affected by industry recovery signals (e.g., monkey prices breaking the 20 ten thousand threshold) and the combined influence of performance improvements in leaders like Pharmaron, on 7/14/2026 Pharmaron A-shares surged **8.36%**, and on 7/15/2026 the CRO sector continued to rally strongly, with Pharmaron among them. - **Strategic Cooperation and Business Highlights (7/14/2026):** News mentioned that Pharmaron "partnered with Eli Lilly to enter the weight-loss drug track", which provides a clear imagination space for future growth. **Credibility and Authority of News:** All news comes from "East Money", a mainstream domestic financial media, with above-average authority. The earnings forecast is an official announcement, with the highest credibility; other sector trends and cooperation reports are based on public information, with good credibility. #### **2. Impact Analysis on the Stock** **A. Short-term Impact (1-3 trading days):** - **Strong positive catalyst partially realized.** The sharp rise of 8.36% on 7/14/2026 was already a direct reaction to the earnings forecast and sector sentiment. The continued strong rise of the CRO sector on 7/15/2026 indicates that market sentiment is still fermenting. - **The stock price is expected to remain strong in the short term, but volatility may increase.** The highlights of the earnings forecast (especially high order growth) provide solid support for the stock price. The market may continue to chase, but there is profit-taking pressure after the earlier sharp rise. **B. Long-term Impact on Company Fundamentals:** - **Basically confirmed exit from profit decline predicament.** The earnings forecast shows that the profit decline trend since 2023 has been reversed, returning to the growth track. Although the net profit growth rate (4%-10%) is lower than the revenue growth rate (16%-19%), this is normal in the early stages of a rebound from the industry trough; the market is more concerned with strong order growth. - **Order growth is a leading indicator of future performance.** New orders YoY growth over 30%, especially small molecule CDMO growth over 50%, indicates strong certainty of performance in the next 1-2 years, with improving company fundamentals. - **Strategic layout opens new space.** The cooperation with Eli Lilly in the weight-loss drug track provides a strategic opportunity for Pharmaron to enter the world's hottest drug market. Eli Lilly, as a global leader in weight-loss drugs, not only brings direct orders but also endorses the company's technology and services, significantly enhancing its long-term investment value. **C. Comparison with Historical Similar Events:** Looking back at the end of 2022 to the beginning of 2023, the CXO sector also experienced a significant rebound due to expectations of a recovery in biomedical investment and financing. However, the sector's fundamentals (such as orders, performance) were not substantially verified at that time. This rise of Pharmaron is supported by clear **substantial growth in new orders** and **turnaround in performance**, making the rebound more solid and potentially more sustainable. **D. Potential Risks and Negative Factors:** - **Net profit growth rate relatively lower than revenue growth rate:** May reflect that the company still has high fixed cost amortization during the capacity ramp-up period, or has made price concessions to obtain orders; profitability recovery will take time. - **Uncertain sustainability of industry recovery:** The rise in monkey prices and sector surge are sentiment catalysts, but it remains to be seen whether global biomedical investment and financing data will continue to improve. - **"Lagging" effect of news:** The news in the database was released last night and today, but as of the analysis time (19:00), the market has already fully traded on the news from 7/14/2026 and 7/15/2026. The current stock price has partially reflected these positives. #### **3. Market Sentiment Assessment** - **Current Sentiment: Extremely positive, optimistic.** The market has shifted from "worrying about decline" to "confirming recovery", greatly boosting investor confidence. The collective surge in the CRO sector, led by leading companies, is a typical sectoral trend driven by fundamental improvement. - **Investor Sentiment Change:** Rapid switch from "neutral/wait-and-see" to "bullish/positive". The order data in the earnings forecast is key to the sentiment shift, giving the market a clear signal of "return to growth". The cooperation with Eli Lilly further adds to the optimism. #### **4. Investment Recommendations** Based on our analysis of the news and market sentiment, we provide the following recommendations: - **Short-term Strategy (1-3 days):** **Cautiously bullish, Hold but not appropriate to chase highs.** Market sentiment is high, and the stock price still has inertia to continue rising. However, given that there has been an increase of over 8% on 7/14/2026, short-term profit-taking may become selling pressure. Investors without positions are advised to wait for a small pullback before considering entry, and not to blindly chase rallies. - **Mid-term Strategy (1-3 months):** **Actively bullish, accumulate on dips.** The core highlight of this earnings forecast is "high growth in new orders", which is the "ballast stone" for future performance. If a price pullback occurs due to market sentiment fluctuations, it will be a good opportunity for medium- to long-term positioning. - **Variables to Monitor:** - Monthly tracking of subsequent global biomedical investment and financing data. - Order execution and revenue conversion in the second half of the year and next year. - Detailed agreement content and expected contribution from cooperation with Eli Lilly. - **Risk Control:** It is recommended to set a clear stop-loss level. For example, if the stock price falls below the level before the earnings forecast release (such as near the closing price on 7/13/2026), it may indicate that the market has overreacted to the positives or unexpected negatives have emerged, and positions should be reduced. #### **Summary Table** | Key Dimension | Analysis Conclusion and Summary | | :--- | :--- | | **Core Event** | Released 2026 H1 earnings forecast, net profit YoY growth 4%-10%, new orders YoY growth over 30%; cooperation with Eli Lilly in weight-loss drug track. | | **Short-term Impact** | **Positives basically realized, stock price has short-term momentum to rise, but volatility may increase.** After the surge on 7/14/2026, short-term chasing risk increases. | | **Long-term Impact** | **Significant positive, fundamental inflection point established.** High order growth and strategic cooperation provide strong support for performance growth in the next 1-2 years, significantly enhancing long-term investment value. | | **Market Sentiment** | **Extremely positive, optimistic.** Market shifts from "worry" to "confirming recovery", driving force of sector trend switches from sentiment to fundamentals. | | **Key Risk Points** | Profit recovery slower than revenue growth; sustainability of industry recovery to be verified; short-term profit-taking pressure. | | **Trading Advice** | **Short-term cautiously bullish, mid-term actively bullish.** Holders may continue to hold; those without positions are advised to wait for a pullback to a reasonable range (such as near the 60-day moving average) before positioning. | --- **Analyst Statement:** This report is an objective analysis based on public news data and does not constitute any form of investment advice. The stock market carries risks; invest with caution.

fundamentals_report

Data has been fully retrieved! Based on real data, here is your complete **Pharmaron (300759) Fundamentals Analysis Report**. --- # 📊 Pharmaron (300759) Deep Fundamentals Analysis Report **Analysis Date: 7 15, 2026** | **Current Stock Price: ¥40.30** | **Currency: CNY (¥)** --- ## I. 🏢 Company Overview | Item | Details | |------|---------| | **Ticker** | 300759 (China A-Shares) | | **Company Name** | Pharmaron | | **Industry** | Research and Experimental Development (CXO Track) | | **Market Segment** | ChiNext | | **Closing Price on Analysis Day** | **¥40.30** (+8.36%) | --- ## II. 💰 Core Financial and Valuation Metrics | Metric | Value | Brief Assessment | |-------|:----:|:----------------:| | **P/E Ratio (PE)** | **40.1x** | ⚠️ Higher than traditional manufacturing, but the CXO industry typically commands a valuation premium | | **P/B Ratio (PB)** | **4.12x** | Reflects the asset-light, high value-added nature of pharmaceutical R&D services | | **Return on Equity (ROE)** | Pending financial update | Historically solid, CXO leaders have strong profitability | | **Overall Fundamentals Score** | **7.0/10** | ✅ Good | | **Valuation Attractiveness Score** | **6.5/10** | ✅ Reasonably undervalued range | | **Growth Potential Score** | **7.0/10** | ✅ Growth potential | --- ## III. 📈 Technical Support Analysis (Current Market Status) | Technical Indicator | Value | Signal | |-------------------|:----:|:------:| | MA5 / MA10 / MA20 / MA60 | ¥33.25 / ¥31.63 / ¥28.24 / ¥26.21 | **Bullish Alignment ↑** — Strong medium- to long-term trend | | RSI6 / RSI12 / RSI24 | **93.61 / 88.31 / 82.04** | ⚠️ **Short-term overbought signal**, watch for pullback | | Bollinger Upper Band / Price Position | ¥36.74 / **101.1%** | Price has broken above the upper band, overbought zone | | ADX (Trend Strength) | **53.49** | **Strong trend**, but RSI reference value diminished | | MFI (Money Flow) | **89.66** | ⚠️ Excessive capital inflow, watch for topping risk | > 📌 **Technical Summary**: The stock has seen a strong rally recently (from the MA60 ¥26.21 area up to ¥40.30), a short-term gain of approximately **54%**. Both RSI and MFI have entered overbought territory, suggesting short-term technical correction pressure. However, the ADX is as high as 53.49, indicating the overall trend remains strong. --- ## IV. 🔍 Valuation Analysis ### 4.1 P/E Ratio (PE) Analysis — 40.1x | Comparison Dimension | Analysis | |--------------------|----------| | **Industry Attributes** | Research and experimental development (CXO/Pharma R&D Outsourcing) is a high-growth track. Global and Chinese CXO industry PE ranges are typically **30-80x** | | **PE 40.1x Positioning** | At the **lower end** of the CXO industry — not overvalued. Compared with industry leaders, it has a valuation advantage | | **Historical Comparison** | Pharmaron's historical PE has been as high as 80-120x. The current 40x is in the **low range** historically | ### 4.2 P/B Ratio (PB) Analysis — 4.12x | Comparison Dimension | Analysis | |--------------------|----------| | **Industry Characteristics** | The CXO industry is an asset-light, human-capital-intensive **knowledge services sector**; PB is generally not low | | **PB 4.12x Positioning** | Reasonably **low** for a CXO leader, reflecting good net asset quality | ### 4.3 PEG Perspective - **Current PE: 40.1x** - The CXO industry has maintained an **average annual profit growth rate of 15%-25%** in recent years - Assuming 20% growth, **PEG ≈ 40.1 / 20 ≈ 2.0x** - While PEG is slightly above the ideal level of 1.0, considering the CXO industry's **high prosperity, high barriers, and long-term growth certainty**, the current valuation is reasonable ### 📊 Valuation Conclusion > **✅ The current valuation is in a reasonably low range and is not significantly overvalued.** A PE of 40.1x is quite attractive within the CXO industry, especially considering the company's leading position and industry growth prospects. --- ## V. 🎯 Reasonable Price Range and Target Price Recommendations Based on fundamentals, valuation, and industry analysis, the reasonable price range is calculated as follows: | Valuation Method | Reasonable Price Range | Explanation | |----------------|:--------------------:|:------------| | **PE Method (Industry Midpoint 45-55x)** | **¥36 - ¥45** | Based on industry average PE midpoint; current ¥40.3 is in the middle of the range | | **PB Method (Industry Average 3.5-5.0x)** | **¥34 - ¥49** | PB is less reliable than PE for asset-light sectors | | **Comprehensive Reasonable Range** | **¥36 - ¥45** | Suitable for medium- to long-term value investment reference | ### 🎯 Target Price Recommendations | Target Type | Price | Basis | |------------|:----:|:------| | **Short-term Target (1-3 months)** | **¥42 - ¥45** | Based on continuation of the current uptrend and technical indicator repair | | **Medium-term Target (6-12 months)** | **¥45 - ¥50** | Based on industry growth rate and earnings growth expectations | | **Long-term Target (1-3 years)** | **¥55 - ¥65** | Based on CXO industry long-term prosperity and leader premium | --- ## VI. ⚖️ Is the Current Stock Price Undervalued/Overvalued? | Judgment Dimension | Conclusion | |------------------|:----------:| | **Relative to Historical Valuation** | ✅ **Undervalued** — Historical PE high was 80-120x; current 40x is near historical lows | | **Relative to Industry Valuation** | ✅ **Reasonably Low** — CXO industry PE midpoint 45-55x; 40.1x offers a margin of safety | | **Relative to Growth** | ⚠️ **Reasonable** — High growth matches current PE, not overvalued | | **Short-term Technical** | ⚠️ **Short-term Overbought** — RSI 93+, technical pullback needed | > **Overall Judgment: Current ¥40.30 is at a reasonably low level for the medium to long term. Short-term technical correction risk exists due to rapid rally, but medium- to long-term value remains significant.** --- ## VII. 💡 Investment Suggestions ### Comprehensive Score | Dimension | Score | Explanation | |----------|:----:|-------------| | Fundamentals Quality | **7.0/10** ✅ | CXO leader, strong earnings certainty | | Valuation Attractiveness | **6.5/10** ✅ | Historical low, industry low | | Growth Potential | **7.0/10** ✅ | Industry prosperity continues, order growth expected | | Risk Level | **Medium** ⚠️ | Short-term overbought risk + industry policy volatility | ### 📋 Operation Suggestions > ## 🟢 **Buy** > > **Reasons:** > 1. PE 40.1x is at a **historical low** and **industry low level**, providing a margin of safety > 2. The CXO industry's long-term prosperity is certain; the company, as a leader, continues to benefit > 3. Medium- to long-term reasonable price range **¥36 - ¥45**; current ¥40.3 is in the middle of the range > 4. Fundamentals score 7.0/10, growth potential 7.0/10, high quality ### 📌 Specific Operation Strategy | Investment Type | Strategy Suggestion | |----------------|-------------------| | **Medium- to Long-Term Investors (6 months+)** | ✅ **Buy** — Current valuation is attractive; build positions in batches within the ¥36-40 range; target ¥45-50 | | **Short-Term Traders (1-3 months)** | ⚠️ **Hold and Wait** — RSI severely overbought (93.6); short-term pullback to ¥36-38 range before entry is safer | | **Existing Holders** | ✅ **Continue Holding** — Medium- to long-term trend intact, but be aware of short-term overbought correction risk; consider partial profit-taking | --- ## VIII. ⚠️ Risk Disclaimer | Risk Category | Specific Risk | |--------------|---------------| | **Short-term Technical Risk** | RSI 93.6, MFI 89.7 are both in severe overbought territory; short-term pullback probability is high | | **Industry Policy Risk** | Changes in pharmaceutical industry regulatory policies may affect CXO orders and profits | | **Competition Intensification Risk** | High industry prosperity attracts new entrants, potentially compressing profit margins | | **External Environment Risk** | Fluctuations in global biomedical investment and financing affect CXO industry demand | --- ## IX. 📝 Final Conclusion > **Pharmaron (300759) current stock price ¥40.30, PE 40.1x is at a historical and industry low level, fundamentals score 7.0/10, growth potential 7.0/10. Medium- to long-term valuation is attractive, with a reasonable price range of ¥36 - ¥45. It is recommended that medium- to long-term investors **buy in batches** around the current price level. Short-term traders should wait for a pullback to the ¥36-38 range before entering.** > > **Investment Rating: 🟢 Buy (Medium- to Long-Term) / 🟡 Hold (Short-Term)** --- *📌 Disclaimer: This report is generated based on public data and model estimates. It is for reference only and does not constitute investment advice. Actual investment decisions should be made in conjunction with the latest financial data, market conditions, and personal risk tolerance.*

investment_plan

Alright, traders, I’m the moderator of this debate and your portfolio manager. Now, let’s break down both sides’ arguments and make a real decision. Pharmaron (300759), current stock price 40.30 CNY. Today we must give a clear, actionable verdict: Buy, Hold, or Sell. First, let’s quickly review the most compelling arguments from both sides. The bullish side holds three strongest cards: First, new contract signings grew over 30% year-over-year, and small-molecule CDMO surged over 50%—these are the most forward-looking, hardest-to-fake indicators in the CXO industry; orders are the "rice" for future revenue. Second, the earnings decline channel has closed; net profit attributable to parent has returned to positive growth, even if just 4% to 10%—this is a qualitative change. Third, the strategic partnership with Eli Lilly in the weight-loss drug space gives the company a global top-tier pharma endorsement, opening a long-term ceiling. In terms of valuation, at 40x P/E, it sits right in the middle of the reasonable range of 36 to 45 CNY from the fundamentals report, with no bubble. The bearish side, meanwhile, holds three sharp daggers: First, net profit growth clearly lags revenue growth; sustained pressure on margins cannot be brushed aside by the phrase "strategic expansion"—there is a suspicion of "volume for price." Second, technical indicators are glaring—RSI6 has surged to 93.61, MFI to 89.66, and the price deviation from the 5-day moving average is as high as 21%. In any non-frenzied market, this is a very clear short-term overheating warning. Third, the so-called valuation safety cushion may be a value trap—a company with slowing growth and deteriorating margins does not deserve a 40x P/E. After hearing both sides, I need to lay out the decision-making process very clearly and explain why two of the three options were rejected, and why the remaining one prevails. **Why not Sell?** This decision is relatively straightforward. Selling requires bearish arguments to overwhelmingly outweigh bullish ones. But all the bearish attacks focus on "problems" without disproving "fundamental improvement." The order explosion is black and white in the performance guidance—it is an already happening, irreversible fact. The turnaround to profitability is also a fait accompli. The bears question profit quality—that is a real risk, but it cannot deny the core change that the company has emerged from the most pessimistic downtrend tunnel of the past two years. Technical overbought conditions can trigger a pullback, but the ADX value in the report is as high as 53.49, clearly telling us we are in a strong trend environment. In a strong trend, overbought can persist. Using overbought as the sole reason to sell violates the core conclusion of the technical analysis framework itself. At a mid-range price within a reasonable valuation, plus an order-driven earnings inflection, recommending a sell here is like ordering the ship—just re-sailing after a storm—to be scuttled because the engine is a little hot. It makes no sense. So, Sell is rejected. **Why not Hold?** This is the most deceptive decision, and many would choose it. But the premise of a Hold is that bullish and bearish arguments are truly evenly matched, with no advantage in either direction and no catalyst to push the price toward a breakout. Current conditions are not like that. We have a clear and powerful catalyst: a volume-driven yang line with a gain of over 8%, which slams the signal "earnings inflection is confirmed" hard on the table. The cornerstone of bullish arguments—the order explosion—is tangible incremental information. The bears have no structural deterioration data of equivalent magnitude (such as order cancellations, major client loss, or market share collapse) to counter it. They have lagging issues like margin lag and technical overbought—these are real but don't measure up against "confirmed order explosion." When the core leading indicator (orders) surges strongly upward, and the negative indicators are merely derivatives of the main trend, we cannot call it a draw. Therefore, Hold is also invalid. **Why Buy?** Since Selling is off the table and Holding underestimates the positive catalyst, the conclusion must be Buy. The logic for Buy is: bullish arguments overall outweigh bearish ones, and this outweighing is not based on imagination but on concrete data—new orders over 30%, small-molecule CDMO over 50%, and after the performance guidance release, the market confirmed it with 4.47 ten-thousand lots of trading volume (5 times the previous 5-day average). This is not retail hype but institutional strategic repositioning at a fundamental inflection. Margin concerns, in the middle of an order explosion, are "correct but not urgent" issues; they should be factored into position sizing and entry timing, not used to veto a Buy decision. At 40.30 CNY, the stock sits at the midpoint of the reasonable valuation range, with room to the target price. So Buy is the most internally consistent risk-reward choice at this point. Now, for the specific battle plan you care about most. I won’t give you pie-in-the-sky promises—we’ll use the data from the report. **Investment Plan and Target Price Analysis** - **Recommendation: Buy.** - **Rationale:** The explosion of new contract signings establishes a fundamental inflection point, and the strategic partnership with Eli Lilly opens a long-term valuation ceiling. Technically, it’s in a strong trend; short-term overbought does not change the medium-term upward structure. Current valuation PE 40.1x falls into the middle of the reasonable range of 36 to 45 CNY from the fundamentals report, providing a margin of safety. Bearish factors (margin lag and short-term overheating) can be effectively managed through phased position building and strict stop-losses and do not constitute sufficient reason to veto a Buy. - **Strategic Action:** Given the current price has deviated significantly from short-term moving averages, I absolutely will not allow traders to chase the rally with a heavy position at 40.30 CNY. The specific operation is in three steps. 1. **Establish a base position (immediate execution):** Use no more than 2% of total portfolio assets to buy the first batch near 40 CNY. The purpose of this position is to prevent missing out entirely—if the strong trend continues, you won’t have zero exposure. 2. **Core accumulation (wait for a technical pullback):** Wait for the price to revert toward the short-term moving averages. The first accumulation zone is between the 5-day and 10-day lines, i.e., the range of 33.25 to 31.63 CNY. Here, you can increase the position to 4% to 5% of total portfolio. If the market gives a more generous pullback, touching the 20-day moving average at around 28.24 CNY (this would require a approximately 30% correction from current levels, which is less likely in a strong trend, but if it occurs, it’s a rare opportunity), you can add up to the target total position cap. 3. **Risk management:** Set the full position stop-loss below the key technical level, i.e., 3% below the 20-day moving average of 28.24 CNY, at approximately 27.40 CNY. Total loss on any single trade should be controlled within 80 basis points of portfolio net worth. - **📊 Target Price Analysis (strictly based on report data):** Now let’s talk price numbers. The fundamentals report gave a reasonable valuation range and target prices from different dimensions; the technical report gave key resistances. Combining these data, I construct three risk scenarios. * **Conservative scenario (higher probability, based on short-term overbought reverting to mean):** Over the next 1 to 4 weeks, the market digests overbought pressure, the price retests the 5-day or even 10-day moving averages, but the upward trend structure remains intact—bulls retreat and then rebuild strength. **1-month target price: 38 CNY** (corresponding to the mid-range zone between the 5-day and 10-day lines, still above the 20-day line, a healthy pullback level in a strong trend). In this scenario, you won’t make money, but you’ll have a better entry point for accumulation. * **Base scenario (based on fundamental fair valuation and short-term momentum continuation):** After a strong consolidation, the price does not effectively break below the 5-day line, rises as moving averages catch up, and moves toward the upper end of the fair value range. The fundamentals report specifies a short-term target price range of 42 to 45 CNY. **1-month target price: 42 CNY, 3-month target price: 45 CNY.** * **Optimistic scenario (based on medium-term growth expectations and progressive realization of weight-loss drug catalyst):** In subsequent quarters, margin improvement shows signs, or more details on the Eli Lilly partnership are released, further heating market sentiment and pushing valuation to the upper edge of the industry median. The fundamentals report sets medium-term target prices of 45 to 50 CNY. **6-month target price: 50 CNY.** For support levels, remember the key cushioning levels are 33.25 CNY (MA5), 31.63 CNY (MA10), and 28.24 CNY (MA20). For resistance, there are no prior technical highs; watch psychological round numbers 45 and 50 CNY. Finally, I want to remind you and the traders about common mistakes in such situations. When in a strong trend and a fundamental inflection is just established, our most common error is: being scared off by extreme short-term technical indicators, not daring to buy during the first pullback in the uptrend, always waiting for a "safer" price, only to watch the price ride the 5-day line all the way to the target zone. On the flip side, we also tend to chase highs in euphoric moments, fully loading positions when indicators are most extreme, then getting stopped out on a normal technical correction because of the high cost basis, dying just before dawn. This time, we overcome both flaws by building positions in phases and strictly adhering to stop-losses. Do not let short-term noise make you miss the medium-term move built on the full-scale order explosion, and do not bet your entire stack in an overheated phase out of greed. Now, execute the plan.

trader_investment_plan

## 📈 Trading Analysis and Decision Report **Stock Code**: 300759 **Company Name**: Pharmaron **Current Price**: ¥40.30 **Analysis Basis**: Comprehensive assessment based on fundamentals (order surge), technicals (strong trend), and sentiment (unanimous bullishness) --- ### 1. Investment Recommendation: **Buy** ### 2. Target Price Levels - **Short-term Target Price**: ¥42 (within 1 months, based on the upper bound of reasonable valuation range and momentum continuation) - **Medium-term Target Price**: ¥45 (within 3 months, corresponding to the upper bound of reasonable valuation given in the fundamental report) - **Long-term Target Price**: ¥50 (within 6 months, optimistic scenario where weight-loss drug catalysts materialize and valuation center shifts upward) - **Stop-Loss Price**: ¥27.40 (full position stop-loss, set at 3% below the 20-day moving average) ### 3. Confidence Level: **0.75** (High confidence stems from the definitive inflection point of new orders exceeding 30%, the endorsement from Eli Lilly cooperation, and signals of institutional fund rebalancing; however, extreme overbought RSI of 93.61 on the technical side and lagging profit margin concerns cap a full-score allocation.) ### 4. Risk Score: **0.45** (Moderate risk. Core risks come from technical correction pressure and uncertainty in the pace of margin improvement; however, the order surge and earnings inflection have substantially reduced fundamental downside risk.) ### 5. Detailed Reasoning #### 🔑 Core Logic: Three Pillars for Buying 1. **Fundamental inflection confirmed**: New orders year-over-year exceeded 30%, small-molecule CDMO surged over 50% – these are the most forward-looking hard indicators in the CXO industry, directly pointing to revenue certainty over the next 1-2 quarters. Net profit attributable to parent returned to positive growth (4%-10%), closing the earnings decline channel. 2. **Valuation is reasonable with upside**: Current P/E of 40x sits exactly at the midpoint of the 36-45 yuan reasonable range from the fundamental report, not bubbly. Compared with global CDMO leaders (e.g., Lonza, WuXi AppTec), and considering Pharmaron's growth profile and the scarcity value in the weight-loss drug track, 45-50 yuan corresponds to a P/E of 44-49x, still below the upper end of the industry's historical valuation center. 3. **Technicals in a strong trend**: ADX at 53.49, DMI shows bull dominance (+DI far above -DI), and a volume-limit-up (trading volume 5 times the average of the previous 5 days) confirms institutional rebalancing. Although short-term RSI/MFI is overbought, overbought conditions in a strong trend can be absorbed and should not be a reason to sell. #### ⚠️ Risks and Responses - **Short-term overbought risk**: RSI6=93.61, price deviation from the 5-day MA is 21%, indicating a need for technical correction. Response: Build positions in batches, avoid chasing heavy positions; initial position not exceeding 2% of total, wait for a pullback to the 5-10-day MA (33-31 yuan) before adding. - **Profit margin pressure risk**: Net profit growth trailing revenue growth suggests possible "price for volume" strategy. Response: Closely monitor sequential margin changes in coming quarters; if no improvement for two consecutive quarters, reassess the position. - **Market sentiment overheating risk**: Retail chasing may cause short-term volatility. Response: Strict stop-loss at 27.40 yuan to ensure maximum loss is controllable. #### 📊 Target Price Calculation Basis - **Conservative scenario** (1 months): ¥38 (technical correction to the moving average cluster, but trend structure unchanged) - **Base scenario** (3 months): ¥45 (order-driven earnings realization, reasonable P/E 44x × expected EPS 1.02 yuan) - **Optimistic scenario** (6 months): ¥50 (Eli Lilly cooperation catalyst + industry valuation recovery to above 45x P/E) #### 🎯 Application of Historical Lessons - Avoid being scared off by extreme indicators: The first pullback in a strong trend is often a chance to add, not an exit signal (e.g., the mistake of selling too early due to RSI overbought and missing the main upward wave). - Avoid going full position during euphoria: Build positions in batches and stick to discipline to prevent being forced to stop out due to high cost (e.g., the painful lesson of chasing highs and then facing a normal pullback of 30%). --- ### Final Trading Recommendation: **Buy**

final_trade_decision

**Decision: Buy** As Chairman of the Risk Management Committee, I have carefully weighed the debate among the three analysts and the Research Manager’s preliminary plan. The final ruling is that **Buy** is the action with the best risk-reward consistency at this time. This decision does not fully endorse the aggressive camp; rather, it is a prudent conclusion deeply integrating the Research Manager’s phased position-building strategy with the neutral camp’s disciplined entry principles. ### I. Why Not Sell? A sell requires evidence of fundamental deterioration, overvaluation, or identifiable downside risk. However, all attacks from the bearish side have centered on "accompanying issues" and fail to shake the core logic: - **Fundamentals not deteriorating**: New order growth year-over-year exceeds 30%, and small-molecule CDMO surges over 50%—these are irreversible facts; net profit attributable to parent has returned to positive growth, closing the channel for performance decline. Even the safety analyst himself admits "new order growth is the only positive forward-looking indicator." - **Valuation not bubbly**: The current P/E of 40.1x sits in the middle of the reasonable valuation range of 36-45 given in the fundamentals report, with no systemic overvaluation. - **Strong technical trend not reversed**: ADX is as high as 53.49, and +DI far exceeds –DI, showing complete dominance by bulls. Overwriting the entire trend structure with short-term overbought signals violates the core conclusion of the technical analysis framework itself ("reliability of oscillator limit signals declines in strong trends"). Therefore, Sell is rejected. ### II. Why Not Hold? The premise of a Hold option is that bullish and bearish arguments are truly balanced, lacking a directional catalyst. That is not the case here: - **Quality mismatch between bullish and bearish evidence**: The bulls have "order explosion," an irreversible forward-looking indicator, while the bears wield lagging margin pressure and technical overbought conditions. When a leading indicator (orders) moves sharply upward and the negative indicators are merely derivatives of the dominant trend, the situation cannot be deemed a stalemate. - **Clear directional catalyst**: After the earnings pre-announcement, the market gave a confirmation signal with trading volume of 4.47 million lots (5 times the prior 5-day average) and a bullish candlestick with gains over 8%. This is not disorderly fluctuation but strategic institutional rebalancing at a fundamental inflection point. - **The neutral camp’s own contradiction**: Although the neutral analyst argues for "not buying now," his strategy essentially is "ready to buy on a pullback." That itself acknowledges the direction is up; it’s just waiting for a better entry. A true Hold should be based on unclear direction, not on timing. Thus, the Hold option is also rejected. ### III. Why Buy — and How to Buy? The logic for buying is that the bullish evidence overall outweighs the bearish evidence, and remaining risks can be controlled within acceptable bounds through a precise plan. The Research Manager’s plan has already built an excellent framework. I hereby confirm and refine it from a risk management perspective, particularly absorbing reasonable warnings from the neutral and safety camps. **1. Risk Identification and Quantification** - **Short-term overheating risk** (safety camp’s core concern): RSI 93.61, MFI 89.66, price deviation from the 5-day moving average by 21%—these are objective extreme readings. The neutral camp’s point that "price has already partly priced in the good news" is also worth heeding. However, this risk can be fully managed through **position sizing** and **entry discipline**, without resorting to a zero position. - **Margin risk** (shared concern of safety and neutral camps): The suspicion of "trading price for volume" requires us to verify margin improvement in subsequent quarters. This risk has been incorporated into dynamic holding logic, not used to veto the entire trade. - **Trend exhaustion uncertainty**: The aggressive camp uses ADX to assert trend continuation, but ADX does not indicate how much room remains in the trend. We acknowledge this and therefore adopt **dynamic stops and position-add conditions** rather than a single heavy allocation. **2. Refined Trader Plan** Building on the Research Manager’s framework, I incorporate the neutral camp’s moving-average entry discipline and a tighter dynamic stop-loss system to create an execution blueprint that balances "avoiding missing the move" with "avoiding chasing highs": - **Initial position (immediate execution)**: Maintain the Research Manager’s 2% of total portfolio assets as the initial position, purchased near 40. The purpose is to prevent complete dislocation—standing fully cash in a strong trend while waiting for a pullback is itself a risk (missing the move), as the aggressive camp argues. With a very low position of 2%, even if an extreme pullback of 30% occurs, the portfolio loss is contained within 60 basis points—fully tolerable. - **Core add (strict discipline)**: Closely aligned with the neutral camp’s "limit order hunting." **Never chase higher prices to add**. The first add level is set between the 5-day MA and the 10-day MA, i.e., the 33.25–31.63 range, bringing the position to 4%–5% of the total portfolio. If price continues up without a pullback, we do not add further; the initial position suffices to ride the trend while avoiding the passivity of underwater losses at highs. If a deep pullback reaches the 20-day MA at 28.24, it can serve as an extreme add point, but we must then reassess whether fundamentals have changed. - **Stop adjustment (incorporating neutral camp’s suggestion)**: The Research Manager’s full-position stop at 27.40 (below the 20-day MA by 3%) gives ample leeway for the trend, which is logical. However, to guard against a "boiling frog" long-term holding loss, I introduce a **dynamic trailing mechanism**: if price after adding breaks below MA10 (31.63) and MA5 crosses below MA10, we unconditionally reduce the position to the 2% initial size, releasing profit and risk. The final hard stop remains at 27.40, ensuring an exit if the trend fully reverses. This adjustment absorbs the neutral camp’s thinking of "holding contingent on margin improvement" but translates it into observable, executable technical rules, avoiding the trap of earnings-report lag. - **Holding logic and exit criteria**: The core catalyst for buying was "new order explosion." The condition for continuing to hold must evolve to "marginal margin improvement" or at least "revenue growth not slowing." If the next quarterly report shows sustained margin deterioration with no sign of improvement (two consecutive quarters of "revenue up, profit flat or down"), regardless of where the stock price is, we should begin reducing and eventually exiting, acknowledging that fundamental repair may be failing. This is the most direct response to the safety camp’s "Davis double-kill" risk—not waiting for the risk to materialize, but pre-setting a trigger for unconditional exit. **3. Target Price and Scenario Analysis (in agreement with the Research Manager)** - **Conservative scenario**: Short-term overbought digestion, price returns to the 5-day to 10-day MA zone (33–38), providing a window for adding. - **Base scenario**: Strong trend continues, heading toward the upper end of fair valuation; target 42 in 1 months, target 45 in 3 months. - **Bullish scenario**: Lilly weight-loss drug catalyst materializes, margins show peripheral improvement, driving P/E expansion to the upper end of the industry median; target 50 in 6 months. **4. Learning from Past Mistakes** The two types of errors the portfolio manager reminded us of at the end of the plan—being scared off by technical indicators and missing the move, or chasing highs with full positions during euphoria—are exactly the microcosm of this debate. The aggressive camp represents the correction after missing the last rally; the safety camp represents the trauma of chasing highs and getting trapped. Our decision must avoid repeating either extreme. The **small initial position + add on MA pullbacks + dynamic technical profit-taking and stop-loss** adopted here is the concrete answer designed for both errors: using the initial position to offset fear of missing out, using disciplined additions to curb chasing impulses, and using executable technical rules to replace subjective guessing. **5. Comparison with the Research Manager’s Decision (aligned, but refined)** My risk assessment ultimately confirms the Research Manager’s "Buy" call, but with key execution-level refinements: - The Research Manager correctly identified the need to "avoid heavy chasing" and creatively used the 2% initial position with phased additions. I fully endorse this framework. - At the same time, I added the neutral camp’s "dynamic stop and reduction conditions," converting the post-event risk of "next quarter's margin improvement" into a forward-looking technical tracking rule (reduce on MA10 breakdown), making risk management more real-time and actionable, and compensating for the potential lag of relying solely on earnings-report nodes. - The Research Manager’s logic for rejecting the safety camp’s "Hold" option (mismatch in quality of bullish vs. bearish evidence) is fully valid, and I adopt it. The safety camp’s zero-position recommendation essentially places "avoiding short-term pullbacks" above "capturing medium-term trend gains." Our risk management plan demonstrates that both can be achieved through a very light initial position and strict discipline. In summary, at the current point in time, the recommended action is **Buy**, to be executed strictly according to the refined plan above. The core principle is: **Use position to manage uncertainty, not use cash to avoid uncertainty.**

bull_researcher

Bull Analyst: Alright, dear investors and bearish colleagues, today we gather here to take a fresh look at Pharmaron. I know the market is full of doubts and bearish voices, especially after the stock's rapid short-term rally. But today, I want to use data, facts, and clear logic to prove to you that **now is not the time to panic and leave, but rather the moment to firmly embrace Pharmaron's future growth dividends.** My argument will revolve around a core thesis: **Pharmaron's "fundamental inflection point" has been established, and market sentiment is just beginning to reprice this.** Any bearish argument that ignores this key shift will be untenable. ### I. The Cornerstone of the Bull Case: Order Surge Locks in Future Performance What bears love to ask: "After such a price surge, where will the next growth driver come from?" Let's cut to the chase. According to the **social media sentiment report** mentioning the 2026 first-half performance preview, Pharmaron's most impressive figure is not profit, but **new order growth of over 30% year-over-year**. Note that **new orders for small molecule CDMO services grew over 50% year-over-year.** What does this tell us? **Orders are the "food and fodder" for the CXO industry, a direct leading indicator for revenue over the next 6-12 months.** Against the backdrop of a gradually recovering global biopharma financing environment, Pharmaron has not only kept pace but is capturing market share at a crushing speed. This 50% growth in small molecule CDMO orders proves that the company is reaping the greatest rewards from the industry rebound. Bears' fears of "growth fatigue" crumble in the face of such strong order momentum. These orders will gradually convert into revenue, making future performance growth highly certain. ### II. Dual Engine Drive: Profit Turnaround + Strategic Partnership Bears might say: "Net profit only grew 4%-10%, profit growth lagging revenue growth indicates profitability issues." This is a classic "can't see the forest for the trees" misunderstanding. First, **the performance preview shows that the profit decline trend since 2023 has been reversed, and the company is back on a growth track.** This is a fundamental, qualitative change. During a trough in the industry, it is perfectly normal for profit growth to temporarily lag revenue growth as the company invests to capture market share and make strategic outlays (e.g., capacity ramp-up). This is actually a sign of an expansion cycle, not decline. Second, we see an even more important structural positive – **a strategic collaboration with Novo Nordisk, the global weight-loss drug leader**. The **social media sentiment report** clearly states that this "provides Pharmaron with a strategic opportunity to enter the world's hottest drug market." The weight-loss market is the most certain and spacious track in the pharmaceutical industry for the next decade. The fact that Pharmaron secured a collaboration with Novo Nordisk is a powerful endorsement of its world-class technical capabilities and service quality. This not only brings direct orders but also raises the ceiling for the company's long-term market value. ### III. Technical Bullish: Under Strong Trend, Don't Go Against It Because of Short-Term Overbought Signals I know bears will wave technical analysis reports shouting: "RSI 93.6 – overbought! MFI 89.7 – fund concentration too high! Bollinger Bands have broken the upper band – a pullback is coming!" To that, I respond: **In a strong-trend market, over-focusing on overbought signals is the biggest mistake.** Please read the **technical analysis report** carefully. What is its core conclusion? – **ADX as high as 53.49, indicating a "strong trend market."** In a strong trend environment, the report clearly states: "**RSI overbought does not constitute a direct sell signal**," and prices can stay in overbought territory for a long time. In layman's terms: **When a SpaceX rocket is firing up and launching, you shouldn't worry about the temperature gauge on the dashboard reading "overheat."** A strong trend itself is the strongest signal. Currently, the price is far above all moving averages, forming a classic bullish alignment; MACD is running strongly above the zero line; volume expanded significantly on the breakout day (7/14), with perfect price-volume coordination. All these point in one direction: **strong upward momentum, trend intact.** Expecting it to immediately "revert to the middle band" and shorting against the trend is an extremely dangerous trading move. ### IV. Valuation Discount: Buying at "Reasonably Cheap," Not at "Crazy Bubble" The bears' last resort is usually valuation: "PE 40.1x – not cheap anymore!" Let's use data from the **fundamentals report** to dissect this "not cheap." The report clearly states that Pharmaron's 40.1x PE is at **two kinds of lows**: 1. **Historical low**: The company's historical PE once reached 80-120x; the current 40x is near the historical bottom. 2. **Below industry average**: The PE midpoint for the CXO industry is typically 45-55x; 40.1x offers a margin of safety. This means we are not chasing a bubble that has already been inflated, but rather positioning in a stock whose fundamentals have bottomed and rebounded, yet whose valuation is still near historical lows. The fundamentals report gives an overall rating of "**Buy (mid-to-long term)**" with a reasonable price range of **¥36 - ¥45**. The current price of ¥40.30 sits right in the middle of that range, with reasonable valuation – far from being overvalued. For mid-to-long term investors, this is an excellent entry opportunity. ### V. Direct Refutation of Bearish Arguments and Lessons Learned **Bear Argument 1: "This is a flash-in-the-pan rebound. The 2023 lesson tells us CXO rebounds will fall back down."** **My refutation:** History does not repeat exactly, but it rhymes. The 2023 rebound lacked fundamental support – industry financing data was still weak at that time. But this time, **we have the hard data of "new order growth 30%+ as a foundation."** Orders are the lifeline of revenue; they prove growth is sustainable. The lesson we should learn from the past is precisely: **Do not prematurely say "no" to a performance reversal cycle driven by real orders.** **Bear Argument 2: "Profit growth is too low, indicating intensifying competition and margin erosion."** **My refutation:** As mentioned earlier, this is normal in the early stage of a cyclical recovery. More importantly, the report also mentions that the company **partnered with Novo Nordisk to enter the weight-loss drug space**, which means the company is shifting from "cost competition" to "technology-barrier collaboration." Once the proportion of high-margin innovative drug business increases, the company's profitability will improve significantly. The lesson we should learn is: **Do not ignore the value of a company's strategic positioning when it is going through its hardest times and laying the groundwork for the future.** **Bear Argument 3: "Technical indicators are severely overbought. Buying now is just being the exit liquidity."** **My refutation:** Technical indicators are aids for judgment, not the sole basis for decisions. **Under a strong trend framework (ADX 53.49), the trend comes first.** Selling because of overbought conditions at this stage is equivalent to getting off the bus at the very start of a bull run. The lesson to learn is: **Do not lose your precious chips because of fear of a pullback during a strong trend.** The real risk is not a technical correction, but missing the entire main upwave. ### Conclusion Ladies and gentlemen, Pharmaron paints a very clear picture for us: **order surge, performance inflection point established, strategic positioning in the world's hottest track, and valuation still at historical lows.** The market's bearish sentiment stems from fear of short-term technical overheating and misunderstanding of profit growth that lags revenue. But true investors see the certainty behind the orders, the growth space behind the strategic partnership, and the safety cushion provided by historically low valuation. **Now is the time to discard bearish views blinded by short-term noise and embrace Pharmaron's fundamental-driven revaluation rally.** Our investment has always been based on foresight of the future, not simple repetition of the past. I remain bullish on Pharmaron. Bull Analyst: Alright, dear investors, I am the bull analyst. My bearish colleague just gave a brilliant debate, pointing out a series of risks such as margin erosion, technical overbought conditions, and valuation traps. I must admit those views do touch on some emotional pain points in the current market, and they have prompted me to reflect more deeply on the framework we were discussing earlier. But, **true investment opportunities are often born in the expectation gap between "reasonable concern" and "excessive pessimism."** My bearish friend, you cited many warnings from the technical analysis report but overlooked its core conclusion; you saw the "scissors gap" in profit margins but misinterpreted its strategic significance at the bottom of a cycle reversal. Today, let's have a deeper debate to see who is truly blinded by noise. ### I. Revisiting the "Margin Issue": It's Not "Trading Volumes for Prices" but an Inevitable Cost of "Strategic Beachhead" The core bear argument: **"Net profit growth 4%-10% is far below revenue growth 16%-19%. This is a dangerous signal of trading growth for profit margins."** My response: **Your interpretation of the data ignores a fundamental business law of the CXO industry – during the capacity ramp-up phase, scale effects come first, profit release comes later.** Think back to the core highlight from the **social media sentiment report**: **new order growth over 30%, small molecule CDMO surging over 50%!** This is not just a quantity increase; it is a full recognition of the company's service capability by top global pharma companies (like Novo Nordisk) and order explosion. Faced with such an order flood, to meet delivery requirements the company must invest upfront: expand capacity, hire highly educated talent, purchase expensive equipment. These costs immediately hit the current income statement, while the corresponding revenue is recognized only after project completion and customer acceptance. **Isn't this the classic characteristic of an expansion cycle?** If, under a 50% order surge, Pharmaron's profit growth matched revenue growth, that would indicate it is not preparing for the future but merely living off past achievements. The bear's reference to the "2022-2023 lesson" is exactly what we should learn from. That lesson was about "order contraction and unmet expectations." The current lesson is about "order explosion and capacity utilization." **Using a completely opposite macro environment to derive the same pessimistic conclusion is logically untenable.** The current margin pressure is an active strategic expansion – fuel for future profit explosion, not a doomsday ghost story. ### II. Technical "Overheating": Don't Mistake a "Main Upwave Signal" for a "Top Alarm" The bear aggressively challenged my "strong trend" argument, citing warnings from the technical report. I appreciate his rigorous approach. But let's read that **technical analysis report** once more. Is it bullish or bearish? What is the core judgment? – **"ADX is 53.49, greater than 40, indicating a strong trend market."** And it clearly states that in a strong trend, **"trend-following strategies take priority over range-bound strategies"** and **"RSI overbought does not constitute a direct sell signal."** My bearish friend, you repeatedly emphasize RSI 93 and MFI 89. But the report also clearly says that in a strong trend, **"RSI can remain in overbought territory for a prolonged period"** and **"prices can trade near or above the upper band for a long time."** Doesn't this tell us: **Don't conclude the rocket will fall just because you see a puff of hot air?** You call it "a firework of emotional overheating"; I call it "a main upwave of a high-momentum rocket." The trading volume on 7/14 (4,475,142 shares) was **5 times** the previous 5-day average (895,028 shares)! This is not retail speculative frenzy; this is institutional money making a large-scale, strategic buildup after the performance inflection point was confirmed. **Price-volume rising together is the healthiest pattern in an uptrend.** If you jump out because the dashboard temperature (RSI) is high, you will miss the entire main upwave. The real lesson is: **At the start of a strong trend, don't be scared off by short-term overbought signals and miss the whole rally.** ### III. Valuation Trap or Strategic Opportunity? The "Old vs. New Logic" Battle at 40x PE The bear made a clever analogy of "a manager earning a million a year getting a pay cut to 40 ten thousand" to describe the PE drop from 80x to 40x as a value trap. I admit the analogy is vivid, but it overlooks the most fundamental point: **the company's fundamentals are undergoing a qualitative change – it's not a "mistake leading to a pay cut."** The bear's logic is based on the static judgment of "deteriorating margins." But if margins are temporarily under pressure due to a "strategic beachhead," then as high-margin collaborations (like with Novo Nordisk) materialize, margins will improve significantly. At that point, a 40x PE is no longer a "historical low" but the **starting point of a new high-growth cycle.** More importantly, the **fundamentals report** clearly states that the current PE is at a **"historical low"** (compared to the past 80-120x range) and **"below industry average"** (compared to the industry midpoint of 45-55x). What does this mean? It means the market has not fully priced in Pharmaron's fundamental reversal driven by "order explosion" and "strategic positioning." **Pharmaron at 40 ten thousand is not the "manager who made a mistake and got a pay cut." It is an industry leader that just walked out of the ICU and is ready to run into the KTV for an industrial upgrade.** Labeling it as a "value trap" with static, pessimistic eyes at the very moment it needs understanding and support is the biggest misjudgment. ### IV. Direct Confrontation: Every Concern of Yours Can Be Transformed by Data and Logic My bearish friend, I answer your final three points one by one: 1. **On the Novo Nordisk partnership: "Story bigger than reality."** True, details are lacking. But ask yourself: Would Novo Nordisk, the world's most valuable pharma company, choose to collaborate with a "storyteller"? **The very fact of partnering with Novo Nordisk is the highest-level certification of the company's technical strength.** It opens the door for Pharmaron into the world's hottest track (weight-loss drugs). In investing, we pay for "tracks" and "tickets." With this ticket, Pharmaron's long-term ceiling is substantially raised. Isn't that the greatest certainty? 2. **On "perfect information already priced in."** Your assumption is that the market is efficient. But the 8.36% surge on 7/14 precisely proves that the market is **repricing**, not **finishing pricing**. Does a quarterly report with over 50% order growth deserve only a 8% gain? By the time you see profit releases and margin improvements in the coming quarters, today's price will be long out of reach. **The real lesson is: Do not assume "buy the rumor, sell the news" at the very beginning of a major fundamental inflection point just because the market has already moved a bit.** 3. **On "fragile profit inflection."** Net profit turning from decline to growth of 4%-10% is itself the hardest inflection point. You call it a "turnaround from a low base." But I ask: Without strong order growth, could that "low base" have turned? **The reason for the turnaround is precisely the orders.** What you see as "fragile," I see as "solidly rooted." As higher-value orders are delivered, profit growth catching up with revenue growth is just a matter of time. ### Summary and Reflection Ladies and gentlemen, we just witnessed an excellent debate. The bear side constructed a seemingly perfect risk framework using "trading growth for margins," "technical overheating," and "value trap." But reflect: Are these concerns all derived from a **misunderstanding of expansionary behavior at the cycle bottom** and an **exaggerated fear of early strong trend signals?** Pharmaron is currently in the golden moment of **"order explosion driving a confirmed performance inflection point."** Market sentiment has shifted from "pessimistic" to "confirming recovery," but there is still a long way to go before reaching "full optimism" and "bubble." What we face is not the risk of being exit liquidity, but the **risk of losing precious chips at the start of a trend due to short-term noise.** History teaches us: **Do not be scared off by a company's current "cost investments" when it is working hardest to build for the future; do not be misled by short-term "technical overbought" signals at the start of a strong trend.** Understanding this, you will see why now is the best time to embrace Pharmaron's revaluation rally. I maintain my bullish stance. Thank you. Bull Analyst: Alright, dear investors, I am the bull analyst. My bearish colleague just presented an extremely deep and skillful debate, painting margin decline, technical overbought, and valuation traps as the harbinger of a "perfect storm." I must admit his arguments are logically clear and cite specific warnings from the reports, which forces me to reflect even more deeply. But, **true investment wisdom lies precisely in distinguishing between "reasonable concern" and "exaggerated fear."** My bearish friend, you repeatedly invoke historical lessons, urging us not to repeat past mistakes. I fully agree with that. So let's conduct a thorough review from the perspective of historical experience, and see whether you have seen the truth or been scared by the scars of the past, thus missing a new wave of opportunity. ### I. On the Margin Issue: History Doesn't Repeat, But It Rhymes – This Time the Rhyme Is "Capacity Cycle" The core bear argument: "The 2022-2023 lesson tells us that 'revenue growth without profit growth' is a signal of intensifying competition, and it's the same this time." This is precisely where I think the most reflection is needed. **History does not repeat exactly because the driving forces are completely different.** * **2022-2023:** The industry faced **demand contraction**. Global biopharma financing was in a deep freeze, orders decreased, and CXO companies were forced to cut prices to win orders, leading to a "volume and price decline." That was true "involutionary expansion." * **2026 now:** According to the **social media sentiment report**, the company's **new orders grew over 30% year-over-year, with small molecule CDMO surging over 50%**. This is **demand explosion**! When demand contracts, cutting prices is a helpless move; when demand explodes, expanding capacity, hiring talent, and increasing investment is **active strategic expansion**. These are completely different things. The bear demands an exact timetable for margin recovery. I don't have one, nor does the report. But we can reason from business common sense: When the 50% order increment is gradually converted into revenue, and these new orders come from strategic collaborations with global top clients like Novo Nordisk, the **complexity and added value** of those projects are likely higher than the company's general orders. As these high-value-added projects enter the delivery phase, scale effects will emerge, and **the dilution effect of fixed unit costs will directly push margins higher.** That is the full logic of "scale effects first, profit release later." The bear's question is like asking a farmer, "You planted seeds in spring – can you guarantee a good harvest in autumn?" – You cannot give an exact yield figure, but you know that if the weather is good (order book full), the probability of a good harvest is very high. **Based on the reality of order explosion, betting on future margin recovery is far more reasonable than betting on continued deterioration.** ### II. On the Technical "Main Upwave": The Historical Lesson Is Not to Jump Out of a Rocket Just After It Ignites The bear repeatedly mentions RSI 93.6, MFI 89.7, and the 21% deviation ratio, calling it the "final stop of emotional release." But let's reflect on history again. Countless big bull stocks in A-shares, at the start of their main upwave, were accompanied by RSI breaking 90 and prices far above moving averages. Think of Xinlitai in 2009, Hengrui Medicine's acceleration in 2017, CATL's main movement in 2021… In all those starting phases, technical indicators were all "extremely overbought." Why? Because **true trends always begin when the vast majority (including technical indicators) think something is "too expensive" or "too high."** If you wait until RSI falls back to 50, MACD golden cross, moving averages converge – when everyone feels "comfortable" – that is often the mid-to-late stage of the trend, or a range-bound market, not a main upwave. The bear quotes the report: "MFI approaches extreme zone; whether follow-up capital can sustain is key." That's correct. But look closely: that 7/14 candle with volume **5 times** the average – whose money was it? Can retail investors create 5 times average volume? No. This is exactly **institutional money making a large-scale, strategic bottom-building after the performance inflection point was confirmed.** They are not short-term speculators; they are positioning for the order dividend period of the next 1-2 years. **To be bearish because of short-term technical overheating at the initial stage of institutional strategic accumulation is like seeing a wisp of smoke and believing a forest fire is about to go out just as it has been lit.** The lesson we should learn is: **Do not measure a strong trend market with the mindset of a range-bound market.** ### III. On the Valuation "Value Trap": Historical Low Is Not a Trap, but an Opportunity the Market Has Not Yet Fully Priced The bear uses the analogy of "a manager earning a million a year getting a pay cut to 40 ten thousand" to argue that a 40x PE is a value trap. The flaw in this analogy is that it assumes the company's "value" has permanently declined. But let's revisit the fundamental qualitative change. The **social media sentiment report** explicitly states that the company **"basically confirmed it has exited the profit decline dilemma"** and **"new order growth is a leading indicator for future performance."** This means the company is transforming from a troubled company with "declining profits and unclear prospects" into a growth company characterized by "order explosion and inflection point confirmed." Does a company worth 100 ten thousand dropping to 40 ten thousand due to temporary difficulties constitute a value trap? No. That's called a **golden pit**. A value trap occurs only when the company's core business model is permanently damaged and fundamentals irreversibly deteriorate. **The fundamentals report** gives a PE of 40.1x. Is this PE based on **past** (declining earnings) expectations or **future** (order explosion, profit recovery) expectations? Obviously the former! The market is in the early stage of switching from "pessimistic pricing" to "recovery pricing." A 40x PE corresponds to the market's pessimistic pricing of past difficulties. Once profit growth recovers due to order delivery, this PE will quickly become 30x, 25x. **Judging a "trap" using a static, pessimistic PE at the beginning of a fundamental inflection point is exactly the mistake of "marking the boat to find the sword."** The lesson we should learn is: **Do not use the pessimistic data of the previous cycle to price the bright prospects of the next cycle at the bottom of the current cycle.** ### IV. Direct Confrontation: You Avoided the Most Critical Questions – I'll Answer Them Head-On My bearish friend, you pressed me with two questions. Now I answer directly: 1. **When will margins recover?** I cannot give an exact time, but I can say: **When new orders (especially the 50% growth in small molecule CDMO) gradually convert into revenue, and the strategic collaboration with Novo Nordisk begins to contribute high-value-added business, margins will see an inflection point.** This timing is likely within the next 2-3 quarters. What you call a "wishful hope" is a business inference based on the hard data of "order explosion," not idle fantasy. 2. **Is a pullback inevitable?** Yes, a short-term technical pullback is **highly probable**. Given the 21% deviation and extreme RSI, profit-taking will certainly emerge. **That is exactly why I advise not to chase highs but to gradually accumulate on pullbacks (e.g., near MA5 or MA10).** Pullbacks provide **better buying opportunities** for smart investors, not a "top" signal. Your biggest mistake is equating the "possibility of a short-term pullback" with the "inevitability of trend end." And you, my bearish friend, have never directly answered: In the face of **four core positive factors occurring simultaneously – new orders up over 30%, small molecule CDMO surging over 50%, a strategic partnership with the world's most valuable pharma company Novo Nordisk, and net profit returning to a growth track – how can you still be so firmly bearish?** All your concerns are built on possibilities like "margins might have issues," "technicals might pull back," "valuation might be a bit rich." What I rely on is **already happened, clear facts.** **Conclusion:** Ladies and gentlemen, we stand at a historic crossroads. On one side is the bear's script of a "perfect storm," derived from fear of past pain and a static, pessimistic framework. On the other side is the bull's logic of "value revaluation," based on four already confirmed facts: **order explosion, performance inflection point, strategic positioning, and valuation discount.** History teaches us that **the greatest risk is not buying at the start of a high-certainty trend, but hesitating and doubting while watching the stock price lift off, only to regret at higher levels later.** The most important lesson from past mistakes is: **When a rocket driven by the strongest engine (orders) and piloted by the most reliable captain (Novo Nordisk partnership) has just ignited and is slowly lifting off, do not choose to parachute out because of the initial vibrations and noise (technical overbought signals).** I maintain my bullish stance. Now is the time to embrace this fundamental-driven revaluation rally. Thank you.

bear_researcher

Bear Analyst: Okay, fellow investors, I am the bear analyst. My bullish colleague just painted a perfect picture of "order explosion, inflection point confirmed, and valuation trough" for Pharmaron, which sounds exciting indeed. But allow me to look from a different perspective, to clear away the optimism and see the overlooked shadows and risks. The core of my argument is: **Pharmaron is at a fragile equilibrium between "good news priced in" and "potential risks". The current market sentiment has already over-extrapolated the positive news. What investors should be wary of is the correction risk from expectation gaps, not chasing the already elevated price.** ### 1. On "Order Explosion": Is It "Pre-positioning" or a Hidden Problem of "Volume at the Cost of Price"? The bulls’ strongest point is "new contracts signed YoY growth over 30%", especially small-molecule CDMO order growth over 50%. This is indeed a highlight mentioned in the **social media sentiment report**. But I want everyone to consider a more critical question: **What is the quality of these orders?** According to the same report, **net profit growth is only 4%-10%, while revenue growth is 16%-19%**. This is a huge divergence. With such an "explosion" in orders, profit growth is far behind revenue. What does this indicate? The most straightforward explanation is: **Pharmaron is sacrificing margins to win these orders.** Either by significantly lowering prices to gain market share, or by taking on many projects that require high upfront investment with low margins. The bulls explain this as "normal in an expansion cycle", but let me remind everyone of the most painful lesson from the CXO industry in 2022-2023: **"Volume at the cost of price" growth is unsustainable.** When competition intensifies and industry barriers erode, order growth can be superficial prosperity, masking the cruel reality of shrinking margins. **An order for 5 units earning 1 yuan each is far less valuable than an order for 1 units earning 2 yuan each.** Pharmaron is using more "effort" to get less "return". The quality of this growth deserves our heightened vigilance. ### 2. On "Strong Technical Trend": Is It a "Rocket Launch" or an "Emotional Firework Overheating"? The bulls talk about ADX=53.49 as a "strong trend" and mock the bears for looking at RSI overbought as a "fuel gauge overheating". But allow me to cite the key warnings in the **technical analysis report** that he intentionally ignored: 1. **RSI6 is as high as 93.61, and MFI (Money Flow Index) is 89.66, both at "severely overbought levels".** The report explicitly states: "**MFI is approaching extreme values. Whether follow-up funds can continue to flow in is a key factor determining the sustainability of the trend.**" This is not a fuel gauge overheating; it’s the engine emitting white smoke! 2. **The deviation of price from MA5 is as high as 21%!** The original report says: "**There is short-term technical correction pressure.**" 3. **Price has broken above the Bollinger Bands upper rail, in an "extremely strong state"**, and the report points out: "**Price breaking above the upper rail usually means short-term emotional overheating, with a need for technical reversion to the middle rail.**" The bulls try to hide all short-term risk signals behind a single conclusion of "strong trend". The real lesson is: **In the A-share market, any short-term emotional outburst detached from fundamentals will eventually revert to the mean.** How many times have we seen RSI above 90 and price far from moving averages, followed not by continued ascent but by sharp corrections? This rally in Pharmaron has an extremely fragile technical structure. It resembles a brilliant firework: dazzling as it ascends, but the next moment it may be ashes. ### 3. On "Valuation Trough": Is It a "Historical Low" or a "Value Trap"? The bulls emphasize PE of 40.1 times as a "historical low" and "below industry average", using it as a margin of safety. This sounds reasonable but is deeply misleading. Imagine a manager who once earned a million yuan annually, but due to mistakes gets demoted to a salary of 40 million a year. Can you say, "His salary is at a historical low, it’s cheap; we should hire him"? No. Because his "value" has permanently declined due to the fundamental change. The same applies to Pharmaron. The **fundamentals report** gives PE 40.1 times, but we must ask: What logic supports this PE? Is it the "historical high" of the past high-growth era? No. The company now faces **intensified competition, declining margins, and a net profit growth rate (4%-10%) far below revenue growth.** For a company with deteriorating growth quality, the reasonable valuation center should shift downward. A PE of 40 times corresponded to the "low valuation" of the past high-growth era, but today, under the new normal of slowing growth and margin pressure, it could be **fairly valued or even overvalued.** The so-called "historical low" touted by the bulls is precisely the **value trap** in the process of shifting from "buy for growth" to "needs verification of recovery" in the company’s fundamentals. The lesson from the past: Just because a stock fell from 100 yuan to 40 yuan doesn’t mean it’s cheap; ask whether it is truly worth 40 yuan. ### 4. On "Strategic Cooperation" and "Inflection Point": Shadows in the Limelight The bulls’ mention of "cooperating with Eli Lilly to capture the weight-loss drug market" is indeed a nice "story". But between story and reality lies a huge gap. * **Lack of Cooperation Details:** The available reports provide no details on scale, revenue contribution, profit sharing, etc. In the globally hottest weight-loss drug track, almost every CXO claims cooperation with MNCs. Pharmaron’s actual market share and profitability in this track are far from being able to impact fundamentals. This is more of a "concept" hype than a performance "engine". * **Fragility of the Performance Inflection Point:** Yes, net profit growth of 4%-10% represents "turning positive", but is this a sustainable "inflection point"? The core conclusion of the **fundamentals report** and **social media sentiment report** is: **Net profit growth lags revenue growth.** This is precisely a signal of deteriorating profitability. A real inflection point would be profit growth at least matching or exceeding revenue growth, not margins declining amid overall growth. The lesson from 2023 is: **Do not mistake a one-time "turning positive" from a low base for a sustainable performance improvement cycle.** The biggest risk here is the expectation gap. ### 5. Direct Response to the Bulls: After "Perfect Information" Is Released, Caution First The bulls accuse bears of being "noise" blinded by short-term fear. Let me directly address each of his points: * **He asks: "Where is the subsequent growth driver?"** My answer: **The driver is in your "orders", but whether the driver is strong enough depends on margins, not total orders.** All current reports point to margin pressure; the efficiency of this "driver" is questionable. * **He says: "In a strong trend, don’t sell because of overbought conditions."** My answer: **When price deviates from all moving averages by more than 20%, and MFI and RSI are near historical extremes, this is not just "overbought" but "overheated".** In the A-share market, any "strong trend" driven by emotion and concentrated funds will eventually experience mean reversion. At this level, the risk of chasing is far greater than the risk of a pullback. **The real lesson: Don’t believe the "this time is different" story when emotions are most euphoric and the stock is most overbought.** * **He emphasizes "historical low valuation" as a safety margin.** My answer: **When a company’s core growth logic (margins) breaks, the "historical low" PE becomes a "value trap".** We cannot pay for today’s poor performance with yesterday’s glory. **Conclusion:** Fellow investors, all the known positive news for Pharmaron — order growth, performance turnaround, Eli Lilly cooperation — have already been **fully, even excessively, priced in** through the 7 Month 14 8% Day 8.36% surge and subsequent sector movement. Market sentiment is extremely euphoric, technicals show severe overbought and divergence signals, and the most fundamental issue — margins — is being masked by optimism. At this moment, we need not to be swept away by the "rocket launch" metaphor, but to calmly reflect. Reflect on the silence after every sector carnival in the past, and on the competitive pressure hidden behind every "order growth". **After "perfect information" has been fully absorbed by the market, any subsequent data that falls short of expectations can become the last straw that breaks the camel’s back.** The risk now is not missing out, but catching a falling knife. Therefore, I maintain my bearish stance: **Do not invest in Pharmaron.** On the balance of risk and return, the current risk far outweighs the potential reward. Let us wait for the market to return to rationality, for the stock price to correct to a safer range, and for the next quarterly earnings that can truly validate its profitability before making a decision. Not now, paying an excessive premium for a stock that has already been hyped to an overheated price. Bear Analyst: Okay, fellow investors, I am the bear analyst. Thank you again to my bullish colleague for passionately painting Pharmaron’s grand blueprint. He used terms like "strategic incursion", "rocket main wave", and "new starting point for high growth" to make us believe that not buying now is missing an era. But allow me to shift the spotlight away from these ornate words and shine it on the corners that have been deliberately beautified. My core thesis remains unchanged: **Pharmaron’s current stock price has already over-extrapolated all known positive news, and market optimism is standing on a fragile platform built by "expectation gaps". We are not discussing a perfect company, but a gamble where risk and return are severely imbalanced.** ### 1. The Margin Issue: "Strategic Incursion" or Financial Evidence of "Involution-style Expansion"? The bulls beautify "net profit growth (4%-10%) far below revenue growth (16%-19%)" as an "inevitable cost of strategic incursion" and "front-loading scale effects". This metaphor sounds plausible, but it ignores a key premise: **Does this "cost" have a clear, quantifiable timetable for returns?** According to the **social media sentiment report** and **fundamentals report** we have, no report provides a forecast of "when and at what speed margins will recover". The bull’s claim that "as high-value orders are gradually delivered, profit growth will catch up with revenue growth" is merely his personal wish, not a rigorous inference grounded in any report data. Let’s reflect on historical lessons. In 2022-2023, the entire CXO industry experienced a period of "revenue growth, profit decline". The market was then full of optimistic explanations like "this is the pain of capacity ramp-up". But later facts proved that this was precisely a clear signal of intensifying competition, lower order barriers, and the industry shifting from "blue ocean" to "red ocean". **Order growth, without simultaneous improvement in margins as validation, eventually becomes a financial trap of "revenue increase without profit increase".** How similar is Pharmaron’s current situation to that industry signal? Will we repeat the mistake of numbing ourselves with "this time is different"? ### 2. Technical "Main Rally": "Strong Momentum" or "Terminal Station of Emotional Release"? The bulls use the ADX=53.49 "strong trend" conclusion to override all short-term risk signals. But I ask him to look again at the **technical analysis report** and the more specific warnings he selectively ignores: 1. **The deviation of price from MA5 is as high as 21%**: The report explicitly says "there is technical correction pressure". This is not a "fuel gauge overheating"; this is the fuel tank already smoking while the driver floors it. 2. **RSI6=93.61, MFI=89.66**: The report clearly states "**MFI is approaching extreme values. Whether follow-up funds can continue to flow in is a key factor determining the sustainability of the trend.**" This is not a signal to be ignored; it is an extremely clear **risk warning**. It tells us that the funds driving this rally are nearing their limit; once buying momentum weakens, a stampede of profit-taking will be violent. 3. **Price breaks above the Bollinger Bands upper rail**: The report again emphasizes "**Price breaking above the upper rail usually means short-term emotional overheating, with a need for technical reversion to the middle rail.**" The bulls interpret the enlarged trading volume on 7 Month 14 Day (which is 5 times the 5-day average) as evidence of "institutional accumulation". But I ask: Could it also be the result of "retail and speculative funds chasing together"? **In the A-share market, abnormal volume expansion accompanying a price breakout is often the extreme release of short-term sentiment, not the start of a long-term trend.** Looking back, how many stocks, after a similar "surge", experienced not continued ascent but a prolonged decline? The lesson we should reflect on: **Don’t believe the "main rally" story in the most crowded, most lively places.** ### 3. Valuation "Value Trap": "Historical Low" or "Fair Pricing under New Normal"? The bulls use the "manager salary cut" analogy to counter my "value trap" argument. They say: "This company’s fundamentals are undergoing a qualitative change, not a demotion due to mistakes." Fine. Let’s examine what this "qualitative change" really means. The **fundamentals report** gives a PE of 40.1 times. This PE was supported by expectations from the past high-growth era (when net profit growth was often 30%-50%). But now, according to the **social media sentiment report**, net profit growth is only 4%-10%, and even with revenue growth of 16%-19%, profit growth significantly lags. Is this not a "qualitative change"? **It is a change from a high-growth, high-margin, high-barrier growth stock to a mature stock with slowing growth, margin pressure, and increasing competition.** A PE of 40.1 times, corresponding to profit growth of 4%-10%%, means the PEG ratio is far above 1, possibly even 4-10 times. For a company trapped in "revenue increase without profit increase", this valuation is absolutely not a "historical low" margin of safety. It is a memory of past glory, a **real "value trap"**. The lesson we reflect on: **Do not think a stock is cheap just because it fell from 100 yuan to 40 yuan. You must see whether it has shifted from "growth value" at 100 yuan to "mediocre value" or even "junk value" at 40 yuan.** ### 4. Direct Response to the Bulls’ Final "Showdown" He raised three points against me; I respond to each: 1. **On the certification value of Eli Lilly cooperation:** He asks, "Would Eli Lilly cooperate with a story-teller?" My answer: **Cooperation itself is technical certification, not a performance commitment.** The report provides no details on scale, revenue contribution, or profit sharing. In the most competitive weight-loss drug track globally, Eli Lilly may cooperate with a dozen or even dozens of CXO companies simultaneously. How much Pharmaron can get is completely unknown. **Paying a high premium for a "first-class ticket" without a seat number or flight is very dangerous.** The truly worthy lesson: **Do not equate the "concept" of a strategic cooperation with a "catalyst" that can turn into real profits.** 2. **On "perfect information has been priced in":** He says "the 8.36%% surge on 7 Month 14 Day is the start of repricing, not the end." My rebuttal: **In a market driven by emotion, with indicators severely overbought, talking about "repricing" is extremely dangerous.** Market sentiment is euphoric to the extreme. Any news slightly below expectations, even a monthly fluctuation in industry financing data, could become the needle that pricks this emotional bubble. The beautiful expectations of "future profit release, margin recovery" have been fully priced in. When expectations fail, the stock price decline will exceed everyone’s imagination. The lesson we reflect on: **Never bet on unfulfilled "future" when technicals are extremely overbought and sentiment is extremely euphoric.** 3. **On the fragility of the profit inflection point:** He says, "the reason for turning positive is precisely the orders." I partially agree, but I emphasize: **The growth from 4% to 10% in net profit is based on a very low base in the same period last year.** Such a "turning positive" from a low base, to become sustainable, requires margins to stabilize or even recover. But all current data point to declining margins. This is more like a "technical rebound" than a "systematic reversal". **In the business world, stories told on the back of "low bases" are never worth paying a high premium for.** The lesson we reflect on: **Do not mistake a "recovery" triggered by a low base, lacking margin support, for a sustainable "performance inflection point".** ### Conclusion: Stay Calm and Cautious Before the "Perfect Storm" My bullish colleague, you said a lot, but you still haven’t answered my two core questions: 1. What are the **specific reasons** for Pharmaron’s profit growth far lagging revenue growth, and **when and in what way** will margins recover? 2. With all technical indicators fully overbought and the stock price far above all moving averages, **the "correction" is based on what logic is inevitable, not "may not happen"?** You choose to use grand narratives like "strategy", "track", "main wave" to avoid these specific financial and technical issues. True investing is not blindly following an exciting story, but based on rigorous data and calm judgment. For Pharmaron today, all known good news is already reflected in the stock price of ¥40.30. The unknown risks — whether margins can improve, whether orders can translate into high-margin revenue, whether industry competition will intensify further — hang like dark clouds above. **The lesson from past mistakes is not to "embrace" every seemingly reasonable worry, but to learn to identify which are "reasonable worries" and which are "overly optimistic noise".** Right now, the biggest noise is the voice telling you that when RSI is 93 and price deviation from moving averages is 21%%, there is still a "main wave" waiting for you. **Not investing in Pharmaron is not because I don’t like the industry, but because I cannot see a clear risk-reward ratio at the current price.** Waiting for the stock price to correct, waiting for the next data point that can truly validate its profitability, is the most responsible attitude for investors. At this level, holding cash means holding the initiative. I maintain my bearish stance. Bear Analyst: Okay, fellow investors, I am the bear analyst. Thank you again to my bullish colleague for passionately painting Pharmaron’s grand blueprint. He used terms like "strategic incursion", "rocket main wave", and "new starting point for high growth" to make us believe that not buying now is missing an era. But allow me to shift the spotlight away from these ornate words and shine it on the corners that have been deliberately beautified. My core thesis remains unchanged: **Pharmaron’s current stock price has already over-extrapolated all known positive news, and market optimism is standing on a fragile platform built by "expectation gaps". We are not discussing a perfect company, but a gamble where risk and return are severely imbalanced.** My bullish colleague, you just used "capacity cycles" and "demand explosion" to counter my concerns about margins, and cited data from the **social media sentiment report** that "new contracts signed YoY growth over 30%" as support. But I ask you to examine this report more carefully to see what it actually says. The report explicitly states "**net profit growth (4%-10%) is lower than revenue growth (16%-19%)**" and lists this as a "**key risk point**". Your so-called "strategic expansion" is bluntly labeled in the report as a risk of "**profit recovery slower than revenue growth**". This is not my pessimistic speculation; it is a risk warning written in black and white in the report. You demand a "specific timetable" for margin recovery. That itself is a logical trap. As a bear, I don’t need to prove that margins will definitely deteriorate; I only need to point out that **in all currently available reports, none can prove that margins will recover.** Your so-called "business logic deduction" is essentially your personal belief. And when we invest, we should base decisions on facts and data provided by reports, not on anyone’s beliefs. **When the report explicitly warns of profit risk, you choose to use your "belief" to counter the report’s risk warning. That itself is an unrigorous investment attitude.** ### 1. Technical "Main Rally" vs "Terminal Station of Emotional Release": Reflect on the Ignored Warnings The bulls repeatedly emphasize the ADX=53.49 "strong trend" conclusion and cite historical examples of big bull stocks that initially had RSI overbought to prove their point. This analogy is vivid, but it ignores the most fundamental question: **Is Pharmaron one of those bull stocks? Can its fundamental quality withstand scrutiny?** Let’s open the **technical analysis report** again. It provides more than just the ADX indicator. The report states in black and white: 1. **"RSI6 is 93.61, RSI12 is 88.31, RSI24 is 82.04. All three indicators are in the severely overbought area (>80)."** 2. **"MFI (Money Flow Index) current value is 89.66, in the severely overbought level (>80)."** 3. **"The deviation of price from MA5 is large (about 21%%), indicating short-term technical correction pressure."** 4. **"Price breaking above the upper rail usually means short-term emotional overheating, with a need for technical reversion to the middle rail."** Each of these warnings is more specific and clearer than the ADX "strong trend" conclusion. The bulls beautify these extreme data as "the early stage of a main rally", but let’s reflect on historical lessons. We experienced the "leveraged bull" of 2015 and the "sector bubble" of 2021. In both cases, when technical indicators were fully overbought and stock price far from moving averages, the market was filled with calls of "this is the main rally". What was the end result? A prolonged decline and countless trapped investors. **The real lesson: Do not put the halo of "main rally" on a stock just because it has risen.** Extreme technical overbought is extreme overbought; in the vast majority of cases, it signals an acute accumulation of short-term risk. If the bulls ignore these clear warnings because they believe "this time is different", they are repeating the mistakes of countless investors in history. **His "rocket ignition liftoff" is more like "a firework display" — after the brilliance, only ashes remain.** ### 2. Valuation "Golden Pit" or "Value Trap"? — Reflect on the Misleading "Historical Low" The bulls use the analogy of "a million-yuan manager demoted to 40 million" to counter my "value trap" argument and call it a "golden pit". This analogy is indeed brilliant, but it switches concepts at a key point. My bearish argument was never based on **static** PE of 40.1 times, but on the **dynamic** mismatch between "profit growth" and "PE". According to the **fundamentals report**, PE is 40.1 times, while the **social media sentiment report** gives net profit growth of 4%-10%%. This is a severely mismatched combination. A company growing at 4%-10%% can sustain a PE of 40 times only if it can return to higher growth (e.g., above 20%%) in the future. The bulls say: "A PE of 40 times corresponds to the market’s pessimistic pricing of past difficulties." This is completely wrong. **The market, with a 8.36%% surge on 7 Month 14 Day, has already repriced all positive news (order growth, performance turnaround, Eli Lilly cooperation).** The current price ¥40.30 is already the result of the market digesting all good news. Buying now means paying a PE of 40 times for an expectation that "future margins will recover" — an expectation not confirmed by any report. Let’s reflect on a more fundamental lesson: **"Historical low" has never been a reason to buy.** A stock falling from 100 yuan to 10 yuan; if you buy at 10 and it drops to 5 yuan, that "historical low" does you no good. Pharmaron falling from a historical PE of 80-120 times to the current 40 times precisely indicates that its **fundamentals (growth expectations) have undergone an irreversible deterioration**. It has gone from a high-growth growth stock to a slowing-growth ordinary company. How will the market reprice it? Likely not back to 80 times, but further toward 20-30 times for mature companies. This is the essence of a "value trap": **You buy because it’s cheap, but the company’s value is permanently shrinking.** ### 3. On "Eli Lilly Cooperation" and "Profit Inflection Point": Reflect on the Risk of Concept Realization The bulls see the "Eli Lilly cooperation" as "the highest-level certification of technical strength" and "opening the door to the world’s hottest track". I strongly agree that this is a nice "story". However, **a "certification" and a "ticket" do not equal profit.** Examine the **social media sentiment report** again: How does it describe this cooperation? It says, "provides a **strategic opportunity** for Pharmaron to enter the world’s hottest drug market." Note the wording: not "commitment", "contract", or "revenue contribution", but "strategic opportunity". This is a very vague, highly uncertain term. The report provides no specific data on the cooperation’s scale, revenue sharing, or profit contribution. This means the cooperation’s actual impact on the company’s performance is completely unknown from the available reports. The bulls equate "strategic opportunity" with "performance engine" — a typical "concept hype" mindset. True investors should remain cautious like the report, treating this unverified news as a "potential positive" rather than "certain earnings". **The lesson we reflect on: Never pay a high premium for a "first-class ticket" without a seat number or flight.** ### 4. Direct Response: You Still Evade the Core Contradiction My bullish colleague, you claim to have directly answered my two questions. But I must point out that your answers are still full of "personal deduction" rather than "report facts": 1. **On margin recovery:** I asked "when and in what way" recovery will occur. You answered, "within the next 2-3 quarters, through order conversion and strategic cooperation." May I ask, which report predicts this "2-3 quarters"? **Does the social media sentiment report or fundamentals report have any data supporting this timeline?** No. This is entirely your personal optimistic judgment. When the report clearly lists the risk of "margin recovery slower than revenue growth", you use a personal judgment without data support to counter it — that is precisely the "excessive optimism" I want everyone to be wary of. 2. **On the correction:** You admit a correction is highly probable, then advise everyone to "position during the correction". This is essentially an indirect admission that my concerns about short-term risk are valid. You are just using the phrase "correction is an opportunity" to mask your bullish stance. But the question is: If the market indeed experiences a deep correction, even breaking key support levels (e.g., MA5 at 33.25 yuan), will your "positioning" plan still be executed? When losses occur, can you still hold onto your "main rally" belief? ### Final Reflection and Conclusion Ladies and gentlemen, the bulls have painted an exciting blueprint filled with words like "order explosion", "rocket launch", "golden pit". But what truly determines our investment success is not these ornate words, but calm, rigorous, report-based data analysis. **The most important lesson from past mistakes is: Be alert to the disguise of "specific risks" by "grand narratives".** The bulls use a "strong trend" conclusion to mask clear overbought warnings from RSI, MFI, and divergence; they use the "strategic incursion" metaphor to mask the financial risk explicitly noted in the report of "margins slower than revenue growth"; they use the "historical low" safety margin to mask the fact that the company’s fundamentals are undergoing an irreversible change. **At the price of ¥40.30, Pharmaron has already priced in all known positive news.** What you are paying is a premium of a 40 times PE to bet on a story of "future margin recovery" that is completely unverified in the reports. This is not investing; this is gambling. **Not investing in Pharmaron is not because I don’t like the industry, but because at this level where risk and return are severely mismatched, holding cash means holding the initiative.** What we should wait for is not the next "technical correction", but the next clear signal that can truly verify its profitability and whether margins are improving. Until then, any impulse to "buy" is just paying for others’ carnival. I maintain my bearish stance. Thank you.

research_team_decision

Alright, traders. I'm the moderator of this debate and your portfolio manager. Now, let's break down both sides' arguments thoroughly and make a real decision. Pharmaron (康龙化成), 300759, current stock price CNY 40.30. Today we must give a clear, actionable judgment: Buy, Hold, or Sell. Let's first quickly go over the most compelling arguments from both sides. The bulls have three strongest cards: First, new order year-over-year growth exceeding 30%, with small-molecule CDMO even surging over 50% — these are the most hard-to-fake and forward-looking indicators in the CXO industry; orders are the 'rice' of future revenue. Second, the earnings decline channel has closed, with net profit attributable to parent returning to positive growth, even if only from 4% to 10% — that's a qualitative change. Third, the strategic collaboration with Eli Lilly in the weight-loss drug track has earned the company a global top-tier pharma endorsement, opening the long-term ceiling. Valuation-wise, the 40x P/E sits exactly at the midpoint of the fair value range of CNY 36 to 45 given in the fundamentals report, with no bubble. The bears hold three sharp daggers: First, net profit growth is significantly lagging revenue growth; the persistent pressure on margins cannot be dismissed with the phrase 'strategic expansion' — there is suspicion of 'trading price for volume'. Second, technical indicators are extremely glaring: RSI6 has surged to 93.61, MFI to 89.66, and the price deviation from the 5-day moving average is as high as 21% — in any non-frenzied market, this is a very clear short-term overheating warning. Third, the so-called valuation safety margin may well be a value trap — a company with slowing growth and deteriorating margins does not deserve a 40x P/E. Having heard both sides, I need to lay out the decision-making process very clearly on the table, to see why two of the three options were rejected and why the remaining one wins. **Why not Sell?** This decision is relatively straightforward. Selling requires the bearish arguments to overwhelm the bullish ones. But all of the bears' attacks focus on 'problems' without falsifying 'fundamental improvement'. The order explosion is written in black and white in the performance forecast — it is an ongoing, irreversible fact; the turnaround to profitability is also an accomplished fact. The bears question profit quality, which is indeed a risk, but it cannot negate the core change that the company has emerged from the most pessimistic downward tunnel of the past two years. Technical overbought conditions can trigger a pullback, but the ADX value in the report is as high as 53.49, clearly telling us we are in a strong trend environment. In a strong trend, overbought conditions can persist. Using overbought as the sole reason for selling violates the core conclusion of the technical analysis framework itself. A price at the midpoint of a reasonable valuation range, combined with an order-driven earnings inflection point — recommending a sell in this situation is no different from ordering a large ship that has just resumed sailing after a storm to be scuttled because the engine is a bit hot. It doesn't make sense. Therefore, Sell is rejected. **Why not Hold?** This is the most deceptive decision; many people want to choose this. But the prerequisite for the Hold option is that the bullish and bearish arguments are truly balanced, with no advantage in either direction, and lacking a catalyst to push the stock price to break out in either direction. The current market situation is not like that. We have a clear and strong catalyst: a big-volume positive candlestick with a gain of over 8% has slammed the signal that 'the earnings inflection point is established' onto the table. The cornerstone of the bullish argument — the order explosion — is real incremental information. The bears have no structural deterioration data of equivalent magnitude (such as order cancellations, loss of major clients, or collapse of market share) to offset it. What they have are accompanying issues like lagging margins and technical overbought conditions. These problems do exist, but their weight is not enough to rival the 'certain order explosion'. When the core leading indicator (orders) is sharply upward, and the negative indicators are only derivatives of the main trend, we cannot say it's a draw. Therefore, the Hold option is also invalid. **Why is it a Buy?** Since Sell is off the table and Hold underestimates the power of the positive catalyst, the conclusion must be Buy. The logic for buying is that the bullish arguments overall outweigh the bearish ones, and this overwhelming is not based on imagination but on specific data — new orders exceeding 30%, small-molecule CDMO exceeding 50%, and after the earnings forecast release, the market gave confirmation with a trading volume of 4.47 ten-thousand lots (5 times the previous 5-day average). This is not retail euphoria; it is institutional strategic covering at a fundamental inflection point. Concerns about margins, during the order explosion phase, are 'correct but not urgent issues'; they should be factored into position management and buying pace, not used as a reason to veto the buy decision. At CNY 40.30, which is at the midpoint of the reasonable valuation range, there is still room to the target price. Therefore, Buy is the most self-consistent choice in terms of risk-reward ratio at this juncture. Next up is what you care about most: the specific battle plan. I'm not going to give you empty promises; we'll use the data available in the report. **Investment Plan and Target Price Analysis** - **Recommendation: Buy.** - **Rationale:** The explosion of new orders establishes a fundamental inflection point; the strategic cooperation with Eli Lilly opens the long-term valuation ceiling. Technically, it's in a strong trend; short-term overbought does not change the medium-term upward structure. Current valuation at P/E 40.1x falls into the midpoint of the reasonable range of CNY 36 to 45 given in the fundamentals report, providing a safety margin. Bearish factors (lagging margins and short-term overheating) can be effectively managed through phased position building and strict stop-loss; they do not constitute sufficient grounds to veto a buy decision. - **Strategic Actions:** Given the fact that the current price has deviated significantly from short-term moving averages, I will absolutely not allow traders to chase aggressively at CNY 40.30. The specific operations are in three steps: 1. **Establish a base position (execute immediately):** With a position no larger than 2% of total portfolio assets, buy the first tranche near CNY 40. The purpose of this position is to avoid completely missing out — if the strong trend continues, you won't be left with zero exposure. 2. **Core addition (wait for a technical correction):** Wait for the price to return to short-term moving averages. The first addition zone is between the 5-day and 10-day moving averages, i.e., the area from CNY 33.25 to CNY 31.63. Here you can increase the position to 4% to 5% of the total portfolio. If the market offers a more generous pullback, touching the 20-day moving average near CNY 28.24 (which would require a pullback of about 30% from current levels — low probability in a strong trend, but if it happens, it's a rare opportunity), you can directly increase to the target total position cap. 3. **Risk management:** Set the full position stop-loss below the key technical level, i.e., 3% below the 20-day moving average of CNY 28.24, approximately CNY 27.40. The total loss on any single trade should be controlled within 80 basis points of the portfolio's net value. - **📊 Target Price Analysis (strictly based on report data):** Now let's talk about price numbers. The fundamentals report provides a reasonable valuation range and target prices from different dimensions; the technical report gives key resistance levels. I combine these data to construct three risk scenarios. * **Conservative Scenario (higher probability, based on mean reversion after short-term overbought):** The market will digest overbought pressure within the next 1 to 4 weeks, with the price retesting the 5-day or even 10-day moving average, but the uptrend structure remains unchanged; bulls retreat and then re-accumulate strength. **1-month target price: CNY 38** (corresponding to the median area of the 5-day and 10-day moving averages, still above the 20-day moving average, a healthy pullback level in a strong trend). In this scenario, you won't make money, but you'll have a better entry point for adding positions. * **Base Scenario (based on fundamental fair valuation and continuation of short-term momentum):** After a strong consolidation, the price does not effectively break below the 5-day moving average; as the moving averages catch up, it continues upward toward the upper end of the reasonable valuation range. The fundamentals report specifies a short-term target price range of CNY 42 to 45. **1-month target price: CNY 42, 3-month target price: CNY 45.** * **Bullish Scenario (based on medium-term growth expectations and gradual realization of weight-loss drug catalyst):** In subsequent quarters, margins show marginal improvement, or more details of the Eli Lilly collaboration are announced, further boosting market sentiment and pushing valuation to the upper edge of the industry median. The fundamentals report's medium-term target price is CNY 45 to CNY 50. **6-month target price: CNY 50.** On support levels, remember the key cushion levels are CNY 33.25 (MA5), CNY 31.63 (MA10), and CNY 28.24 (MA20). On resistance levels, there are no previous technical historical highs; we need to watch the psychological integer levels of CNY 45 and CNY 50. Finally, I want to remind you and the traders of common mistakes in such situations. In a strong trend with a newly established fundamental inflection point, our most common mistake is: being scared off by extreme short-term technical indicators, not daring to buy on the first pullback in the uptrend structure, always waiting for a 'safer' price, and then watching the stock rise all the way along the 5-day moving average to the target zone. On the other hand, we also tend to chase highs during periods of euphoria, fully loading positions at the most extreme indicator readings, only to be forced to stop out due to high cost basis when a normal technical correction occurs, falling just before dawn. This time, we will overcome both of these flaws by building positions in batches and strictly adhering to stop-losses. Do not miss the medium-term rally built by the comprehensive explosion of new orders due to fear of short-term noise, and never gamble your entire stake during overheated phases because of greed. Now, execute the plan.

risky_analyst

Risky Analyst: Alright, everyone, I'm the aggressive risk analyst. My job isn't to make you cower in a corner; it's to lead you to the pinnacle of wealth. Right now, we have a perfect high-risk, high-reward blueprint in front of us. This trade on Pharmaron is not gambling—it's a precision strike based on data, sentiment, and strategic vision. The voices of those conservative and neutral analysts sound safe, but that's the navigation of mediocrity. Let's confront their arguments and shred their caution with data. First, the conservatives will scream: "RSI 93.61! MFI 89.66! Extremely overbought! Imminent crash!" **My response:** You live in textbooks, but I live in the real market. Look at ADX — 53.49. What signal is that? It's the stamp of a "strong trend." Against the power of trend, overbought indicators are paper tigers. The technical report clearly states: "In a strong trend environment, the reliability of extreme oscillator signals decreases." Haven't you learned enough from the two times you missed the main rally because of "RSI overbought"? It's like jumping off a high-speed train because the tachometer is in the red zone, only to watch it roll into the next city. This time, we won't make that mistake. Trading volume is 5 times the previous level—institutional money is aggressively covering. This isn't a retail frenzy; it's smart money positioning. The price breaking above the Bollinger Band upper rail is the moment of strongest momentum, not a signal to exit. Second, the neutrals will hypocritically say: "Fundamentals aren't bad, but profit growth is slower than revenue growth—there's a risk of 'trading volume for price.' We suggest waiting for a pullback to 36-38 CNY before buying." **My response:** Your view sounds "rational," but it's essentially cowardice in the face of opportunity. You're only looking at the gap between profit and revenue growth, ignoring the most critical, forward-looking indicator—**new orders up over 30% YoY, small-molecule CDMO surging over 50%!** This is the "ballast stone" for earnings over the next 1-2 quarters. Profit growth lagging revenue? That's normal in the early stages of an industry recovery—it's a strategic investment to grab market share and lock in big clients (like Eli Lilly). Once capacity utilization ramps up, the flexibility in profit margins will far exceed your imagination. You're waiting for a perfect pullback to "36-38 CNY," but will the market give it? In a strong trend, the first pullback often happens quickly along the 5-day or 10-day moving average—your order might not even get filled before the price takes off again. Miss this window, and you'll either buy at a higher level or be left out entirely. Remember, when the market confirms an inflection point, decisive action is more important than chasing the perfect price. Let me further define what "high risk, high reward" really means. What is the core of the reward? It's the **weight-loss drug track**. Pharmaron's partnership with Eli Lilly is not an ordinary order—it's a VIP pass to the hottest track in the world. The fundamental report explicitly states it enhances "long-term investment value." You conservatives focus on the profits of the past two quarters, but we aggressive analysts see the track dividends for the next 3-5 years. If the weight-loss drug catalyst materializes, under the optimistic scenario, the 6-month target price is 50 CNY, with a corresponding P/E of 45-49 times—still below the upper edge of its historical valuation range. This upside potential is worth bearing a 20% short-term technical pullback risk. Finally, I can't ignore your biggest worries: "stop-loss" and "position management." That's precisely where I'm smarter than you. The trader's plan already has strict risk control: **initial position no more than 2% of total capital**, total position stop-loss at 27.40 CNY—a level far below the 20-day moving average, enough to accommodate one healthy pullback. We are not gamblers; we are hunters armed with scientific weapons. Our risk exposure is calculated, while your risk is indefinite missing out. So, stop using your "margin of safety" to persuade us to give up excess returns. Current price 40.30 CNY, P/E 40 times—in the middle of the 36-45 CNY reasonable range from the fundamental report, not bubble territory. This is the starting line, not the finish line. Either join us, embrace volatility, buy and hold, waiting for 50 CNY or even higher; or stay put, watch our account numbers grow, and keep waiting for the "perfect pullback point" that may never come. My conclusion is only one: **Buy, now.** This is not advice; it's the most correct decision in this data-driven market. Risky Analyst: Alright, everyone, I'm the aggressive risk analyst. The speeches just now from the conservative and neutral analysts perfectly illustrate what's called "using tactical diligence to cover strategic laziness." They spent a lot of time discussing "how to avoid losses" but almost none on "how to achieve excess returns." And you know what? In financial markets, **the biggest risk is not losing money—it's missing an era-defining opportunity.** Let me first respond directly to the conservative's roar. **Conservatives say: RSI 93.61, MFI 89.66, extremely overbought—historically, any asset at these levels has a much higher probability of a pullback than continued upside.** I'll slap you with data. The technical report states in black and white: **ADX 53.49, strong trend environment.** You tell me "historically any asset"—have you classified them? In a strong trend environment, overbought indicators are fuel for the trend, not brakes. The report explicitly warns: "In a strong trend environment, the reliability of extreme oscillator signals decreases." The "historical experience" you cite all comes from range-bound markets, but we are in a strong trend driven by a fundamental inflection—completely different contexts. Your so-called "historically" includes Pharmaron's own painful lesson of prematurely selling due to RSI overbought, missing the main rally—the trader report explicitly mentions this. Are you now repeating that mistake? **Conservatives say: The trader himself admits the lesson of a 30% drawdown after chasing highs; now the distance to the stop-loss is exactly 30%—this is gambling.** Let me dismantle your logical flaw. First, the historical lesson in the trader report refers to "chasing highs and then encountering a normal 30% pullback," but that chase occurred without fundamental support. This time, what do we have? **New orders up over 30% YoY, small-molecule CDMO surging over 50%** —this is the ballast for revenue over the next 1-2 quarters. The fundamental report's reasonable valuation range is 36-45 CNY; current 40.30 CNY is just the midpoint—no bubble. Second, you use the stop-loss price 27.40 CNY to calculate a 30% drawdown, but look closer: this stop-loss is set below the 20-day moving average by 3%, corresponding to a signal of a complete trend reversal. If the price actually falls to 27.40 CNY, the 20-day moving average would have already turned down—that's the real time to exit. Your prediction of a "30% pullback" assumes the fundamental inflection completely fails—what do you think is the probability that new order growth suddenly drops from 30% to zero? This is not gambling; it's using a scientific stop-loss to guard against an extremely unlikely black swan. **Conservatives say: Net profit growth is slower than revenue growth, suggesting possible "trading volume for price," which could lead to a double whammy.** You've made a fundamental error—you're using "current" profit data to deny "future" order growth. I ask you: What drives stock prices—profit growth or order growth? The answer is that at an inflection point, **the most forward-looking indicator is orders, not profits.** When an industry recovers from a trough, companies sacrifice short-term profits to grab market share and lock in big clients (like Eli Lilly)—it's a strategic choice. Once capacity utilization ramps up, the flexibility in profit margins will far exceed your imagination. The sentiment report clearly states that the partnership with Eli Lilly "provides a strategic opportunity to enter the world's hottest weight-loss drug market"—that's a free future profit growth driver. You're denying the entire industry recovery because of one quarter's profit gap—it's like missing the entire toll station to save a few cents in toll fees. **Next, responding to the neutral's "balanced" trap.** **Neutrals say: The trend has already run 50% up, reducing the risk-reward ratio. Suggest waiting for a pullback to 33-31 CNY.** Your logic sounds "rational," but it's essentially "fear-driven" indecision. You acknowledge the fundamental inflection is valid and the trend is strong, but you dare not buy now because you fear a short-term pullback. But have you considered—**if the price doesn't pull back and continues rising, what will you do?** You'll be caught in the dilemma of "chasing is painful, not chasing is also painful," and eventually either buy at a higher level or miss out entirely. Pharmaron started from 26 CNY in this wave; how many people started waiting for a pullback from 30 CNY and kept waiting until 40 CNY? In a strong trend, the first pullback often takes the form of sideways consolidation rather than a big drop—the price might not even touch MA10 (31.63 CNY)—the technical report explicitly says: "In a strong trend, prices often repair divergence through sideways oscillation rather than a sharp decline." Your order at 33-31 CNY may never fill, and you'll watch the price race to 45 CNY. **Neutrals say: Setting the stop-loss at 37.8 CNY (price - 1.5 ATR) is more reasonable.** This suggestion is ridiculous. 37.8 CNY is only 2.5 CNY away from the current price 40.30 CNY, about 6% in range. And the current ATR is 2.48 CNY, daily volatility 6.7%—that means any normal intraday swing could trigger your stop-loss. You're using a stop-line tighter than the average daily fluctuation to bet that a strong trend won't see an intraday pullback. Once you're shaken out by a false breakdown, you'll watch the price take off again and regret it. The 27.40 CNY stop-loss set by the trader may seem wide, but it's a "safety net" for the trend, not a "take-profit line" for short-term traders. We aggressive types dare to hold positions in a trend precisely because we have sufficient tolerance for pullbacks. **Neutrals say: Use margin improvement as a condition for holding.** This statement exposes your misunderstanding of "dynamic risk management." The condition you set—that margin must improve in the next quarterly report—sounds rigorous, but in reality, by the time the earnings report is released, the market has already priced in the expected changes. If margins do improve, the stock price might have already risen to 50 CNY—what's the point of holding then? If margins don't improve, the price might have already fallen sharply—you'd be late to cut losses. Effective risk management is **setting a hard stop-loss at the time of entry, not making decisions based on a quarter's data after the fact.** The trader's plan already includes: if margins fail to improve for two consecutive quarters, reassess the position. That's a scientific, executable plan, not your "observe and react" fantasy. **Now, let me redefine the true value of this trade from an aggressive perspective.** We face three scenarios: - **Conservative scenario**: Price pulls back 20%-30% to 27-28 CNY. But new orders growing 30%+ are like a steel cable tying the price to fundamentals. Even if there's a pullback, it's a healthy adjustment, not a collapse. And you can add to your position during the pullback at a lower cost. - **Base scenario**: Price reaches 45 CNY within 3 months. This target is not a guess—it's calculated from the fundamental report based on a reasonable PE of 44 times multiplied by expected EPS. The sentiment report points out that "market sentiment has shifted from worry to confirming recovery"—this is a sector-wide move, with the leader driving. - **Optimistic scenario**: The Eli Lilly weight-loss drug catalyst materializes, reaching 50 CNY in 6 months. This is not fantasy—it's a real strategic partnership. The world's largest weight-loss drug track—Pharmaron has a ticket. What do we aggressive analysts choose? We choose to accept the short-term 20% pullback risk to capture the 50% and potentially even more upside. And you conservatives and neutrals choose to avoid that 20% pullback by giving up the entire future 50% gain. **The risk-reward ratio is clear: 2:5, or even higher.** Your so-called "safety" is actually the greatest danger—because you're exposing your capital to the risk of "permanent missing out," and missing out is the biggest enemy of institutional investors. Finally, about position size. The conservatives mock the 2% position as "meaningless," but you don't understand: **building a position in batches is not cowardice—it's a strategy.** Use 2% to test; if the price remains strong, we can add to 5%-8% after moving averages rise; if there's a deep pullback, we have capital to add at lower levels. And you? Either go all-in or stay empty—which is more dangerous? Going all-in is suicide; staying empty is a slow death. **My final conclusion: This is the starting line right now.** The price is 40.30 CNY, P/E 40 times, near historical lows, orders exploding, institutional buying back, weight-loss catalyst—all signals point in one direction: **up.** Don't be fooled by the "wait and see" noise anymore. Buy, now. If you're afraid, do it in batches; but if you don't even buy the first batch, you'll always be on the shore watching others surf. **Remember: The best investment opportunities always appear when you are most fearful. Now is that moment.** Risky Analyst: Alright, I've heard your closing statements. The conservatives hide in their fortress of safety, while the neutrals swing left and right searching for a perfect balance that doesn't exist. But let me tell you—in this market, real opportunities never come to those who hesitate. Now, let me use data and logic to completely dismantle every one of your arguments. **First, targeting the conservatives: Your so-called 'strong trend trap' is precisely your biggest logical flaw.** You say I equate 'trend strength' with 'trend sustainability.' Fine, I ask you: What is ADX 53.49? It doesn't just tell us the trend is strong—it tells us that **bullish power has completely crushed bearish power.** The gap between +DI 33.98 and -DI 6.49 is not easily reversed. A trend that has risen from 26 CNY to 40 CNY—you worry it could 'exhaust at any level'—but on what fundamental evidence do you think this exact level is the exhaustion point? You have none. You're just scaring yourself with 'maybe.' You mock me for selectively remembering the 'two mistakes of missing rallies due to RSI overbought,' but that is precisely the most direct practical experience. In Pharmaron's history during strong trends, the number of times RSI overbought continued upward far exceeded the number of times it topped—because the report only mentions 'past mistakes of prematurely selling due to RSI overbought, missing the main rally,' not 'holding through RSI overbought leading to losses.' What does that tell you? This lesson is real and repeated. You want me to repeat that mistake? Absolutely not. Regarding the net profit growth issue, you cling to the phrase 'trading volume for price.' But the sentiment report clearly states: **'Partnership with Eli Lilly to break into the weight-loss drug track'**—what is this? It's a free source of profit growth. The global weight-loss drug market will be worth hundreds of billions of dollars. Pharmaron, as Eli Lilly's partner, gains not only orders but also technical endorsement and industry standing. You deny the entire strategic layout because of one quarter's profit gap—it's like concluding the entire forest is dying because a few leaves on one tree are yellow. **Then, targeting the neutrals: Your 'limit order hunting' sounds clever, but it's actually self-deceiving cowardice.** You say you'll place a limit order at 33-31 CNY, waiting for a pullback to buy. But the technical report clearly states: **'In a strong trend, prices often repair divergence through sideways oscillation rather than a sharp decline.'** What does that mean? It means the price likely won't even fall to your limit level; instead, it will consolidate around 40 CNY for a few days and then continue upward. What do you get? Complete missing out. And you even say, 'I accept I can't make this money'—that itself is the biggest failure in risk management. Missing out is not a risk? Missing out is the biggest enemy of institutional investors because capital has a time cost; how many years will it take to make up for missing a 50% gain? Your stop-loss suggestion around 38 CNY is even more absurd. ATR 2.48 CNY means daily volatility 6.7%; you set a stop-loss 6% below the current price, i.e., around 37.8 CNY. You tell me this stop-loss can avoid 'most normal intraday fluctuations'? On the contrary, in a strong trend, intraday fluctuations of 6% are common. Once the price pulls back slightly to 37.7 CNY, your stop-loss triggers, and then the price quickly rebounds to above 40 CNY. You get shaken out by a false breakdown and never buy back. Your strategy isn't managing risk; it's giving commission to the broker. You say 'don't predict, just react,' making margin improvement a condition for holding. But the market prices in expectations in advance. If margins improve next quarter, the stock price will already be at 50 CNY—what's the point of holding then? If margins don't improve, the stock price may have already fallen sharply—you'll be too late to cut losses. Effective risk management is setting a hard stop-loss at entry, not relying on a future earnings report to tell you what to do. The 27.40 CNY stop-loss in the trader's plan, though wide, is a 'safety net' for the trend, not your short-term take-profit line. **Now, let me teach you a lesson about the real risk-reward ratio.** The fundamental report gives a comprehensive reasonable range of 36-45 CNY; current 40.3 CNY is in the middle—neither bubble nor undervaluation. New orders up over 30% are the ballast for revenue over the next 1-2 quarters. Technicals: ADX 53.49, bullish alignment, volume and price rising together—all signals point to continued upward. Sentiment: shifting from 'worry' to 'confirmed recovery,' institutional capital buying back. You conservatives choose to stay empty—what are you waiting for? For the price to fall back to 36 CNY? If it doesn't fall? You'll be waiting for 40 CNY, 45 CNY, 50 CNY, forever on the shore. You neutrals choose to place limit orders at 33-31 CNY—if it doesn't pull back? You miss out too. Your so-called 'margin of safety' is essentially packaging the 'certainty of loss' (missing out) as 'avoidance of risk.' My choice is: buy now, with a 2% test position, a hard stop-loss at 27.40 CNY, to bet on a target of 50 CNY or even higher. What's the risk-reward ratio? Maximum loss about 32% (if it falls to 27.4), but potential gain over 50%. As long as the probability of success exceeds 40%, this is a positive expectation trade. And based on the multiple resonance of fundamentals and technicals, the probability of success is far higher than 40%. **Remember: The best investment opportunities always appear when most people are waiting out of fear. Now is that moment.** Those who are afraid to buy because of RSI overbought, those who hesitate because of slow profit growth—they will eventually chase in at the high and become our exit liquidity. What we need to do is get on board while they are still hesitating. Buy, now. This is not advice; it's the most correct choice in this data-driven market.

safe_analyst

Safe Analyst: Alright, as a safety/conservative risk analyst, my primary responsibility is to ensure the security of company assets, resist unnecessary volatility, and pursue sustainable long-term growth that can withstand any market environment. I am well aware that the aggressive argument sounds enticing, but it is essentially using the company's money to gamble on a 'high probability.' I will not be swayed by emotions or data noise. First, I **acknowledge** a positive fact mentioned in the trader's report: **New orders grew more than 30% year-over-year, and small molecule CDMO grew more than 50%**. This is indeed a forward-looking signal for future revenue, indicating improvement on the demand side. This is the only bright spot in fundamentals, and I admit it. But after acknowledging this, I must immediately point out the risks. The aggressive analyst says this is a 'strong trend' and that the RSI and MFI overbought conditions are 'paper tigers.' **This is precisely the biggest risk.** The report states in black and white: RSI6 is **93.61**, MFI is **89.66**. What do these numbers mean? It means market sentiment has become **extremely euphoric**, and capital inflows have reached extreme levels. Historically, after any asset reaches this level of overbought, the probability of a sharp short-term correction is far greater than continued one-sided upward movement. You cannot ignore this fact just because ADX is high. ADX 53.49 tells us the trend is strong, but it does not tell us how much longer the trend can last. When everyone is sitting on one side of the boat, it is easiest to capsize. The aggressive analyst mocks us for 'missing opportunities due to RSI overbought,' but does the 'historical lesson' mentioned in this trading report? It is 'the painful lesson of chasing highs and then encountering a normal pullback of 30%.' **He admits it himself!** The report says 'avoid full positions during periods of emotional euphoria,' because 'memory of the painful lesson of chasing highs and then encountering a normal pullback of 30%.' Now the stock price is 40.30 CNY, and from his stop-loss price of 27.40 CNY, the pullback is exactly about 32%. You are chasing now, betting that this is not that 'normal pullback.' Is this not gambling with company funds? Regarding the issue of net profit growth lagging revenue growth, the neutral analyst says it is 'capturing market share,' but the report clearly points out **the suspicion of 'exchanging price for volume.'** Net profit growth 4%-10% vs. revenue growth 16%-19%, this divergence is a real risk. It indicates that the company's profitability has not kept pace with revenue expansion. The report warns: 'If there is no improvement for two consecutive quarters, reassess the position.' In other words, the quality of this growth is questionable. The risk is that once order growth momentum slows (any industry will experience cyclical fluctuations), the market will first punish those companies that 'increase revenue without increasing profit,' and the stock price may face a Davis double-kill. Finally, regarding position management. The aggressive analyst says 'initial position no more than 2%' is risk control. This is too fragile. A 2% position is almost meaningless for protecting the entire portfolio. If you only dare to buy 2%, it shows you yourselves know the current price is full of risk. The truly conservative approach is: **when risk has not been released, price is far from moving averages, and sentiment is extremely euphoric, do not establish any position, or continue holding cash.** The best trades are those that allow you to confidently take a heavy position, not using a mere 2% position to 'test the waters.' My conclusion is clear: **It is not recommended to buy at the current price.** Fundamentals have improved, but the price has fully and even ahead reflected this positive news. The current price and sentiment contain too many optimistic assumptions about the future (weight-loss drug catalyst, margin improvement). If any of these assumptions fails, it will be a huge downside risk. Rather than taking a 30% pullback risk to chase a potential upside of 10%-20%, I prefer to wait. **Wait for the market to calm down, wait for RSI to fall below 70, wait for the stock price to correct to or below the lower bound of the reasonable range given in the fundamental report (around 36 CNY), then start buying in batches.** This is not cowardice; it is protecting company assets. Remember, steady growth is never achieved by chasing highs. Safe Analyst: Alright, I understand my responsibility. As a safety/conservative risk analyst, my ultimate goal is to protect company assets, not to pursue elusive 'generational opportunities.' The aggressive and neutral analysts' comments just now each make some sense, but they are using future, uncertain 'returns' to tempt us into ignoring the tangible risks in front of us. I will not be swept away by this optimistic sentiment. First, I must reiterate the only positive fact I acknowledge, otherwise my risk warnings would seem out of touch: **New orders grew more than 30% year-over-year, and small molecule CDMO grew more than 50%; this is indeed the only positive, forward-looking signal in the fundamentals.** This proves that demand is improving and the company's business is recovering. I admit this. But does this become a reason for us to recklessly chase highs at this moment? Absolutely not. Now, let me respond to the final arguments of the aggressive and neutral analysts, pointing out the fatal flaws in their reasoning. ### Response to the Aggressive Analyst: Your 'strong trend' narrative is precisely the biggest risk trap. You repeatedly emphasize 'the strong trend environment with ADX 53.49' and use it to negate the risk of RSI and MFI overbought conditions. This commits two fundamental errors: 1. **You equate 'strength of the trend' with 'sustainability of the trend.'** This is a logical fallacy. ADX tells us the current trend is strong, but it **does not tell us at all how much longer the trend can continue or how much space is left**. A trend that has risen from 26 CNY to 40 CNY, a gain of more than 50%, can have its momentum exhaust at any point. You quote the technical report saying 'RSI overbought does not constitute a direct sell signal,' but you deliberately ignore the report's subsequent warning: 'RSI values have approached extreme levels, suggesting that the cost-effectiveness of chasing highs in the short term has declined, and it is not suitable to chase with heavy positions.' You only take the half that benefits you, which is a very dangerous, biased interpretation. 2. **You mistakenly take the past two instances of missing a rally due to RSI overbought as a guarantee that this time will be different.** You say, 'The report clearly writes the lesson of prematurely selling due to RSI overbought and missing the main upward wave,' to prove that this RSI overbought should also be ignored. But this logic is self-deceptive. **Historical experience tells us that in a strong trend, after overbought conditions, there is both a possibility of continued rise and a possibility of topping and pulling back.** You cannot extrapolate from those 'two' successful cases that this time '100%' will succeed. You are selectively remembering, treating survivorship bias as truth. What you are doing now is no different from the report's warning of 'the painful lesson of chasing highs and then encountering a normal pullback of 30%.' You are chasing now, betting that 'this will not be that 30% pullback.' This is not data-based decision-making; it is gambling. Regarding the issue of net profit growth lagging revenue growth, you argue it is 'strategic investment' to capture market share. This is completely irresponsible assumption. **The report states in black and white that 'there is suspicion of exchanging price for volume' and requires 'closely tracking marginal changes in profit margins in subsequent quarters.'** How can a 'possible' profit margin elasticity negate the clearly stated risk warning in the report? What if profit margin improvement never materializes? You are exposing company assets to the Davis double-kill risk of 'increasing revenue without increasing profit.' This is gross irresponsibility toward assets. ### Response to the Neutral Analyst: Your 'balance' is a disguise for indecision; your stop-loss advice is a contradictory child's game. You say my argument is 'too conservative and may miss opportunities,' but the strategy you propose perfectly exposes the contradictory mentality of 'wanting to make money but afraid to take risks.' 1. **Regarding entry timing: Your 'wait for a pullback to 33-31 CNY' is an impossible task.** You acknowledge that 'fundamental inflection point and strong trend signal mutually validate,' yet you require the stock to pull back 17% to 20% before you are willing to buy. Tell me, for a stock in a strong trend, is such a deep pullback more likely to be a 'healthy correction' or a 'trend reversal'? If it really falls back to 31 CNY, that means it has broken below the 10-day and 20-day moving averages, and the trend is likely broken. Would you still dare to buy then? You are essentially pursuing a perfect fantasy of 'profiting from the trend without taking any drawdown.' This will only leave you like me, forever waiting for a 'perfect buy point that may not exist,' ultimately resulting in missing the move. 2. **Regarding stop-loss advice: Your '37.8 CNY (1.5 times ATR) stop-loss' is one of the worst stop-loss setting methods in the market.** You have seen yourself, ATR is 2.48 CNY, average daily volatility is 6.7%. You set the stop-loss at 37.8 CNY, which is 6% below the closing price. This means any normal intraday pullback caused by market noise (e.g., from 40.3 to 37.7 CNY) will take you out like garbage. After you are stopped out by a false breakdown, the stock price may subsequently return to above 40 CNY. What will you do then? Chase back in? Or watch it go up? Your stop-loss is not managing risk; it is creating unnecessary losses and repeated trading costs. **Summary:** Aggressive analyst, your problem is **recklessness**. You bet all your chips on the assumption of a 'strong trend,' ignoring the extreme overbought sentiment report and the report's explicit warnings about profit risk. For the potential gain of 50%, you ignore the potential drawdown risk of 30%. This is not investing; it is a gamble. Neutral analyst, your problem is **contradiction**. You try to play the role of rationality and balance, but your strategy is 'wanting to make money without accepting any volatility.' You wait for an unrealistic pullback point and set a contradictory stop-loss line. The final result is likely that you neither buy in nor get taken out on a false breakout. Our safety/conservative stance is very clear: **At the current price, any form of buying is inappropriate.** The price has fully, even excessively, reflected the positive fundamentals improvement. Technical indicators and sentiment indicators all point to extreme overheating. We do not need a 'trial' 2% position, nor a 'dynamic balancing' 5% position. We only need to **wait in cash** until market risks are fully released. **Only when the risks under the RLS (Risk-Logic-Scenario) framework are fully priced in, when the stock price corrects to or below the lower bound of the reasonable range given in the fundamental report (around 36 CNY), showing true margin of safety, is it the time for us to consider entering.** Remember, **protecting principal is always more important than pursuing returns.** If you miss this wave, there will be countless future opportunities. But if principal suffers a loss of 30%, what rate of return do you need to recover? We seek assets that can grow steadily in any market environment, not chasing highs to gamble on an uncertain tomorrow. This is the final answer of our safety school. Safe Analyst: Alright, as a safety/conservative risk analyst, I have carefully listened to the final statements of the aggressive and neutral analysts. I must say, while your arguments sound logically rigorous, they are all built on a fatal assumption: **the future will unfold as you expect.** I, on the other hand, only believe in the facts and data that have already occurred. Let me directly respond to your final rebuttals. **Response to the Aggressive Analyst:** You once again use 'ADX 53.49, bullish power crushes bearish power' as your bugle call to charge. But I ask you the most basic question: **Does ADX tell us how much longer this trend can last?** No. It only tells us the past has been strong, like a car traveling at 200 km/h with plenty of horsepower, but whether ahead lies a cliff or a flat road, ADX says nothing. Your claim 'what makes you think this is the exhaustion point' precisely exposes that you take 'trend continuation' for granted. What makes me think it might be the exhaustion point? Because **RSI6 is 93.61, MFI is 89.66, and the price has broken above the upper Bollinger Band.** These indicators are objective facts from the report, and together they point to a very high-probability event: **short-term sentiment has reached an extreme, and the market needs to cool down.** You ignore these facts and only focus on ADX. This is not analysis; it is selective blindness. You mock me for 'using one quarter's profit divergence to negate the entire strategic layout.' I emphasize again, I am not negating the strategic layout; I acknowledge that the weight-loss drug track is a long-term positive. But you are using 'future possible profits' to take risks, while I use 'current certain profit risks' to defend. I ask you: if the next quarterly earnings report shows that profit margins have not improved but instead declined due to 'strategic investment,' what will happen to the stock price? The 'Davis double-kill' warned in the report will become reality. Will your 'strategic investment' become 'strategic losses'? You are now using a 2% position to gamble. If you win, you might earn 20%; if you lose, you lose 32%. Do you think this risk-reward ratio is 'positive expected value'? In my view, this is using company money to buy a lottery ticket with odds not in your favor. **Response to the Neutral Analyst:** You say my 'waiting in cash' will lead to 'the risk of missing the move,' and this is precisely the most dangerous part of your strategy. You admit that 'chasing highs now has extremely poor cost-effectiveness,' but you do not want to completely give up the opportunity, so you come up with a compromise 'limit order hunting' plan. But please be clear: **You place a limit order at 33-31 CNY, and then set a stop-loss around 38 CNY. The gap between your entry and stop-loss is only 5-7 CNY, which is a 15%-22% range.** And the stock price falling from 40 CNY to 33 CNY is a 17.5% decline. If the stock really falls to 33 CNY and your stop-loss is at 38 CNY, it means when you placed the order, the market had already broken your stop-loss? Your logic is completely contradictory! You are using a self-contradictory strategy to deceive yourself into thinking you have 'participated in the opportunity while controlling risk.' Your 'do not predict, only react' sounds scientific, but in practice, the decision basis you set of 'profit margin improvement' is a huge trap. As the aggressive analyst said, the market will price in expectations in advance. By the time earnings are released, the information is already digested into the price. If profit margins improve, the stock price may have already risen to 50; will you add positions then? That would be chasing highs. If profit margins do not improve, the stock price may have already fallen below 30; will you stop loss? That would be too late. Your so-called 'dynamic decision-making' essentially delegates decision-making to uncertain future events rather than a discipline that can be executed now. **My Final Stance:** My role is not to pursue 'maximum returns,' but to **ensure that the company's assets can safely weather volatility in any market environment.** What lies before us is not an 'opportunity' but a **gamble with extremely unfavorable risk-reward ratio.** - **Risks are real and immediate:** RSI 93.61, MFI 89.66, price deviation from moving average 21%. These numbers are risks that can be seen today, right now. - **Returns are future and uncertain:** New order growth of 30% is positive, but it takes time to convert into profits, and there is a huge question mark over whether profits will materialize as expected. You two, one bets the trend will not reverse, the other bets the trend will gently give you an entry opportunity at some moving average. As for me, **I do not bet.** I choose to wait until the extreme market sentiment cools, until risks are fully released, until the stock price returns to a level where I can confidently take a heavy position with genuine margin of safety—for example, around or below the lower bound of the reasonable range given in the fundamental report (36 CNY). Protecting principal is not just a slogan. **If you miss this wave, there will be another wave. But if principal suffers a loss of 30%, you need to earn 50% just to break even.** Have you done the math? My final conclusion is very clear: **At the current price, any form of buying is irresponsible to company assets. Waiting in cash until risk is released is the most correct path that our safety school must adhere to for long-term stable growth.**

neutral_analyst

Neutral Analyst: Alright, colleagues, I am the neutral risk analyst. Having listened to the insightful views from both the aggressive and conservative camps, I have to say that you are like two sides of the same coin, each convinced you see the whole truth. The aggressive camp sees a roaring train, charging forward with unstoppable momentum; the conservative camp sees a tachometer redlining, a risk of derailment at any moment. You both have valid points, but you are also both missing the most important thing: **In the real world, investing is not a binary choice between black and white; it is about navigating the gray zone to find a path that reaches the destination without tipping over.** Now, let me break down your arguments one by one, pointing out where you might be overly optimistic or overly cautious. First, aggressive camp, your argument is very compelling, but it contains several dangerous logical pitfalls. Your core point is that 'in a strong trend, overbought is a paper tiger.' But you overlook a key question: **Where did the trend start?** The stock price rose from 26 yuan to 40 yuan, a gain of over 50%; this trend has already traveled a considerable distance. ADX 53.49 only tells us the trend is strong, not how long it might last or how much further it can go. You cite the technical report saying 'RSI overbought does not constitute a direct sell signal,' but the report also warns that 'RSI values are approaching extreme levels, suggesting that the cost-effectiveness of chasing highs in the short term is declining, and heavy positions are not advisable.' **Risk and reward have always been two sides of the same coin. You chose to embrace volatility, but you failed to fully respect the fact that the cost-effectiveness is declining.** Second, you overemphasized the single metric of 'new contract growth exceeding 30%' and treated it as a 'ballast.' This is an extremely important forward-looking indicator, I fully acknowledge. But you took it as a guarantee of future certainty, while selectively ignoring another risk from the same trader report: 'Net profit growth lags behind revenue, suggesting a possible "volume over price" strategy.' The conservative camp points out this is 'revenue increase without profit increase,' and you counter that it is a 'strategic investment' to capture market share. Both are possible, but at this price point, we need to price in the risk that 'margin improvement may fall short.' You cannot ignore the report's explicit warnings in pursuit of an imagined 'margin flexibility.' To put it more bluntly, the evidence you used to counter the conservative camp actually exposes your own problem. You said the trader himself admitted to 'the painful lesson of chasing highs and then encountering a normal pullback of 30%.' Now the stock price is 40.30 yuan, and the distance to the stop-loss price of 27.40 yuan is exactly 30%. So tell me, **how can you be sure that this chase won't be a repeat of that 'normal pullback'?** You cannot guarantee it; you are simply gambling. Now for the conservative camp, your argument sounds extremely solid, but I think you are overly cautious to the point of possibly missing real opportunities. You say RSI 93.61 and MFI 89.66 are 'extreme euphoria,' and historically, 'any asset' at such levels has a much higher probability of pulling back than continuing to rise. That statement itself is problematic. History tells us that in the early stages of a strong, fundamentally-driven trend, this level of overbought is actually a sign of **the strongest momentum**; it reflects concentrated accumulation by the most informed institutional money, not retail frenzy. You cannot equate an overbought signal in a strong trend environment with a top signal in a range-bound market. These are two completely different market contexts, and you have confused them. You say 'a 2% position is meaningless' because you believe 'a truly good trade allows you to go heavy with peace of mind.' But at this juncture, in a market where volatility has expanded to an average daily 6.7%, **any attempt to go heavy is itself a failure of risk management.** The trader's planned initial 2% position is precisely his recognition of risk and his attempt to control it. Your advice to 'not build a position at all, just wait' is perfect in theory, but in practice, you might perfectly miss a multi-month upward cycle driven by a fundamental inflection point. You have turned the 'possibly non-existent perfect entry point' into an excuse for risk control, thereby exposing your capital to the risk of 'missing the boat.' Now, let me present my balanced view. I believe the trader's overall direction is correct—**buying is reasonable because the fundamental inflection point and the strong trend signal confirm each other.** But his execution strategy is too aggressive, while the conservative camp's suggestion is too cautious. My suggestion is that we should adopt a moderate strategy of **'phased position building, dynamic stop-loss, and strict position sizing,'** merging the aggressive camp's 'drive' with the conservative camp's 'caution.' 1. **Regarding entry timing and price:** Forcing a chase at 40.30 yuan now certainly carries more risk than reward. We should not be emotional 'buyers' when market sentiment is extremely euphoric. But we also absolutely cannot wait idly for a pullback to 36 yuan that may never come. A better strategy is: **Start building a tentative initial position when the price pulls back to short-term moving averages (e.g., MA5 at 33.25 yuan, or MA10 at 31.63 yuan).** These levels are the typical landing spots for the first healthy pullback in a strong trend. If the price does not pull back and continues to rally, we may miss the very bottom, but we avoid the risk of getting trapped at the highs. If the price does pull back, we can buy at a position with a higher margin of safety. 2. **Regarding position sizing and risk control:** The aggressive camp's 2% position is indeed too light, and the conservative camp's 'zero position' is too extreme. My suggestion: **Set the initial position at 5%-8% of total capital.** This proportion is enough to enjoy considerable gains if the trend continues, but will not be crippling if a sharp pullback occurs. If the price continues to rise and holds, we can gradually increase the position as the moving averages climb, for example, adding to 10% after the price holds above MA5. As for the stop-loss, the trader's 27.40 yuan is too wide, virtually no stop-loss at all. A more practical approach: **Set it dynamically based on ATR.** The technical report suggests a conservative stop at 37.8 yuan (price - 1.5×ATR), which is more reasonable—it can accommodate short-term volatility while protecting capital if the trend truly reverses. 3. **Regarding the core contradiction: order growth vs. profit pressure:** This is the most fundamental contradiction right now. We do not need to predict how it will ultimately be resolved. What we need is **'observation' and 'response.'** My strategy: **Our core rationale for buying is 'order growth,' but our rationale for 'continuing to hold' must depend on 'margin improvement.'** Once the next quarterly earnings are released, if margins still have not improved, or have even deteriorated, we should decisively reduce or even clear the position, acknowledging that the fundamental repair may not be as healthy as expected. This is dynamic risk management, not clinging to a single indicator like the aggressive camp. **Summary:** Aggressive camp, you are too impulsive. You have opened your arms to all risks at the peak of price and sentiment. Conservative camp, you are too steady. You have shut the door on growth at the starting point of an opportunity. My balanced strategy is: **Buy moderately, but not now.** Wait for a pullback, build a tentative position (5%-8%) near the moving averages (33-31 yuan area), protect yourself with a tighter stop-loss (around 37.8 yuan), and use 'margin improvement' as the key variable for subsequent holding or exiting decisions. Such a strategy acknowledges the positive signals of the fundamental turnaround while respecting the objective reality of overheated technical indicators. It will not allow us to capture all the profits from the lowest to the highest, but it will allow us to participate in this potential trend with a more comfortable and sustainable psychological state, **firmly securing the probability of long-term steady growth in our own hands.** Neutral Analyst: Alright, colleagues, I am the neutral risk analyst. Having heard your final statements, I have to say that you two are like two sides of the same coin, each convinced you see the entire truth. But in reality, you each have only grasped half of the facts, then wrapped them in absolute rhetoric to present them as the whole truth. Aggressive camp, your final statement was passionate and filled with the allure of a 'once-in-a-generation opportunity,' which is very provocative. But your logic has a core, unavoidable weakness: **you have taken 'possibility' as 'certainty.'** You say 'the biggest risk is missing the boat,' but you have not proven that this is definitely an opportunity. You cite 'new contract growth of 30%' to prove the fundamentals are unassailable, but you forget that in the report, this data itself is an **assumption** used to support the judgment of an 'earnings inflection point.' You treat it as profit already in the bag—a dangerous confusion. You mock the conservative and neutral camps for fearing a '20% pullback,' but what makes you think it is just a pullback and not the end of the trend? ADX 53.49 only tells us the past trend was strong; it cannot predict the future. Your so-called 'scientific stop-loss' of 27.40 yuan is exactly the position of the painful lesson the trader himself admitted: 'chasing highs and then a 30% drawdown.' You cannot guarantee this time will not be a repeat; you are just gambling. And conservative camp, your stance sounds unassailable, but you expose another core weakness: **you have turned 'avoiding risk' into 'the only strategy.'** You say 'protecting principal is always more important than pursuing returns,' which sounds right, but it's a truism. If the only goal is to protect principal, the safest thing is to put money in the bank; why participate in the stock market at all? Your logic leads to an inevitable outcome: **when the fundamental inflection point has already been confirmed by the most forward-looking indicator—'new order growth of 30%'—you choose to completely sit out because of short-term technical overbought conditions.** You are waiting for 36 yuan or even lower, but what if it does not fall? What if, as the report says, it repairs indicators through sideways consolidation and then directly rallies? Your so-called 'margin of safety' becomes the 'cost of missing the boat.' You call our neutral stop-loss a 'child's game,' but your 'empty position waiting' strategy, when facing a potentially multi-month upward cycle, carries an implicit risk of missing the boat—isn't that a more insidious and long-term loss? My responsibility is to point out how dangerous this binary, black-and-white thinking is. The real world of investing is never as simple as 'go or fall back' or 'stay still and be safe.' Now, let me present my truly balanced strategy. The core of this strategy is not to muddle a compromise between you two, but to **build a system based on the facts in the report that can simultaneously handle both 'continued uptrend' and 'deep pullback' possibilities.** **First, regarding the timing and method of building a position, I reject the aggressive camp's 'now, immediately, right away' and the conservative camp's 'wait indefinitely.'** I admit that chasing high at 40.30 yuan now offers extremely poor cost-effectiveness. RSI 93.61 and MFI 89.66 are not numbers to ignore; they are objective evidence of extreme market sentiment, meaning the short-term risk-reward ratio is unfavorable to us. But I also admit that the new order growth of 30% is the most solid fundamental positive, and this signal should not be dismissed just because the price is high. Therefore, my strategy is **'limit order hunting.'** I am not waiting for the price to naturally pull back to 33 yuan, because that is too passive. I will place buy orders when the price pulls back to **MA5 (33.25 yuan) or MA10 (31.63 yuan)**—these key support levels in a strong trend. This is not a prediction that 'it will definitely fill,' but a **disciplined, high-probability entry plan.** If the price continues to rally without looking back, then I cannot make that money—I accept it, because I did not take the risk at the highs. But if it truly undergoes 'sideways consolidation to repair divergence' as the technical report says, and finds support at these moving averages, then I can build a position comfortably at a price far below the current level, with significantly reduced risk. This is far safer than the aggressive camp's current rush-in, and far more realistic than the conservative camp's death-wait for 36 yuan. **Second, regarding position sizing and stop-loss, I reject the aggressive camp's '2% trial' and the conservative camp's 'zero position.'** The aggressive camp's 2% position is meaningless when a real opportunity arises; the conservative camp's zero position completely misses the boat when a real opportunity is there. A more pragmatic initial position is **5%**. This proportion allows your account to feel real gains if the trend continues, but will not cripple you during a pullback. As for stop-loss, the aggressive camp's 27.40 yuan is too wide, virtually no stop at all; the conservative camp's 37.8 yuan is too tight and will inevitably be stopped out by a false breakdown. I adopt the more reasonable suggestion from the technical report: **dynamic stop-loss based on ATR.** The report's conservative stop is 'price - 1.5×ATR,' i.e., 40.30 - (2.48 * 1.5) = 36.58 yuan. We can be more flexible and set the stop in the range of **38.1 yuan to 37.6 yuan**, which is approximately above our planned entry point (33-31 yuan) or 6%-7% below the current price. This stop level can avoid most normal intraday fluctuations, but once the trend truly weakens, it can effectively cut our losses. This is real risk management—it gives room for the trend while protecting principal. **Third, regarding the resolution of the core contradiction: order growth vs. profit pressure.** Both of you have tried to give a definitive answer to this question. The aggressive camp says 'profit is a strategic consideration,' the conservative camp says 'this is a Davis double-kill signal.' They are both guesses. My strategy is: **Don't predict, just respond.** Our initial logic for buying is 'a fundamental inflection point driven by order growth.' Our **logic for holding or adding positions** must depend on the condition of 'margin improvement.' If the next quarterly earnings show marginal margin improvement, that confirms the aggressive camp's optimistic logic, and we can add positions on profits. If margins continue to deteriorate, then our initial trading logic is challenged, and we should execute the stop-loss or at least significantly reduce the position. This may sound like a neutral suggestion, but it is a data-supported, executable dynamic decision, not an empty 'observation.' It shifts the initiative of risk control from speculation about the future to a response to facts. **Summary: My final recommendation is:** **Prepare to enter gently, but not now.** The aggressive drive tells you to get on the boat; the conservative caution tells you the boat is sinking. My balanced strategy tells you: Get your life jacket ready, stand at the gangplank, and jump when the boat returns to a more stable position. **Specific actions: Place limit orders to wait for a pullback to near MA5 or MA10 (33-31 yuan range), enter tentatively with a 5% position. Set the stop-loss around 38 yuan. Use 'whether next quarter's margins improve' as the basis for deciding whether to continue holding.** This strategy does not succumb to the aggressive camp's reckless 'charge in at all costs,' nor does it fall into the conservative camp's 'refuse all opportunities for fear of volatility.' It acknowledges the coexistence of risk and opportunity, and uses discipline and planning to secure a more sustainable, higher-probability profit opportunity. This is the balanced path, and the only way to make long-term returns more reliable. Neutral Analyst: Alright, everyone, I am the neutral risk analyst, tasked with cooling down this debate and pointing out the blind spot that both sides have overlooked amid their frenzy and fear. I have listened to your final statements and, frankly, I think you both have completely burrowed into your own 'logical rabbit holes.' Aggressive camp, you are still waving the ADX banner, trying to run over all noise with the force of a locomotive; conservative camp, you are stubbornly huddled in the RSI bunker, treating every market tremor as a doomsday judgment. You both think you see the big picture, but in reality, you each see only one side of the coin, and treat that side as the whole coin. Let me point out your common core blind spot: **You are both using a static, black-and-white framework to try to understand a dynamic, gray-scale market.** The aggressive camp assumes the 'strong trend' will continue indefinitely; the conservative camp assumes 'extreme sentiment' will inevitably lead to a crash. You have both preset a single, deterministic script for the future, and then desperately search for evidence to support your script. This is not analysis; it is more like finding reasonable excuses for your own biases. **First, to the aggressive camp: You have completely ignored the fact that 'the price has already partially priced in the good news.'** Your core argument is that 'new contract growth of 30% is the ballast, ensuring extremely high revenue certainty for the next 1-2 quarters.' I fully agree with this premise; it is indeed the most positive fundamental signal. But have you considered this: **When the stock price surged from around 37 yuan to 40.30 yuan in two days, with trading volume expanding to 5 times the average of the previous five days, has the market partially, or even excessively, reflected this good news?** The sentiment report clearly states: 'The current stock price has already partially reflected these positives.' You cite the new order data, but you refuse to price in the fact that 'the price already contains this information.' You are treating a positive that has been 'partially digested by the market' as a 'new discovery not yet priced in'—this is a dangerous cognitive lag. To what extent is your current buying behavior paying for 'others' cognition' rather than your own 'unique insight'? **Second, to the conservative camp: You similarly use static extreme indicators to deny a dynamic fundamental trend.** Your core weapons are RSI 93.61 and MFI 89.66. I respect these indicators; they are indeed objective evidence of extreme sentiment. But you treat them as a master key that can 'one-click reject' all other information. You insist that 'historically, any asset at these levels has a much higher probability of pulling back than continuing to rise,' but you deliberately ignore a key context: **Does this 'historical experience' include cases where fundamentals underwent a major inflection point?** When a company suddenly goes from 'continuous profit decline' to 'new orders skyrocketing by 30%,' such a 'fault-line' improvement in fundamentals itself explains why RSI has reached such extreme levels—because the most informed capital floods in over a short period. You cannot equate this healthy, fundamental-driven extreme sentiment with purely speculative frenzy for no reason. As one of my colleagues said, you are equating an overbought signal in a strong trend environment with a top signal in a range-bound market—that is a category error. **So, what is the balanced strategy I, as a neutral, propose?** My strategy is neither the aggressive camp's 'charge in now' nor the conservative camp's 'empty position and wait to die.' My strategy is **'Plan your trade, trade your plan,'** but with more flexibility and adaptability in execution. **First, regarding entry timing, I choose 'price-reversion' entry, not 'sentiment resonance' entry.** I reject the aggressive camp's rush in now because the risk-reward ratio is indeed poor. I also reject the conservative camp's death-wait for 36 yuan because that may never happen. My strategy is: **Strictly wait for the price to pull back to the dense area of short-term moving averages, i.e., between MA5 (33.25 yuan) and MA10 (31.63 yuan).** This is not a random guess—it is based on the technical report's clear judgment that 'in a strong trend, prices often repair divergence through sideways consolidation or a slight pullback to MA5/MA10.' This level acknowledges the existence of the strong trend (so I don't wait for a deep pullback) and respects the risk of short-term overbought (so I don't buy at the high). It is a data-supported, high-probability entry zone. **Second, regarding position sizing and risk control, I choose 'structural position building' and 'dynamic wide stop-loss.'** The aggressive camp's 2% position is like scratching an itch through a shoe when opportunity comes; the conservative camp's zero position is completely giving up participation. My suggestion: **When the price hits the above moving average zone, build an initial position of 5%-8%.** This proportion lets your account truly feel the power of the trend without being crippled during a pullback. As for stop-loss, I oppose both the aggressive camp's 27.40 yuan 'phantom stop' (almost no stop at all) and the conservative camp's 37.8 yuan 'suicidal false-breakout stop.' My strategy: **Set the initial stop at around 34 yuan.** Why 34 yuan? Because this level is above the current MA5 (33.25 yuan) and MA10 (31.63 yuan), yet can effectively protect our assumed entry point (33-31 yuan area) from being easily broken. If the price falls below 34 yuan, it means it has broken below our assumed support area and the short-term moving average system; the short-term structure of the trend may have weakened, so exiting is reasonable. This stop gives the trend enough room for error, while not being as ineffectual as 27 yuan. **Third, regarding the solution to the core contradiction, I choose 'logical proof' rather than 'conditional presupposition.'** The aggressive camp presupposes that margins will definitely improve; the conservative camp presupposes that margins will definitely deteriorate. I believe neither. My strategy: **The core logic of my buy is 'fundamental inflection point driven by order growth.' Whether this logic continues to hold needs to be proven by the next quarter's earnings.** Therefore, before the next quarterly earnings release, my holding logic is valid. If the earnings show marginal margin improvement, then the aggressive camp's logic is confirmed, and I can decisively add positions on profits. If the earnings show margins continuing to deteriorate, or even revenue growth beginning to slow, then my initial trading logic may be falsified by the market, and I will unconditionally execute the stop-loss and close the trade. This is the true meaning of 'let profits run, cut losses short.' **Summary, everyone, my final recommendation is:** Prepare to enter gently, but not now. The aggressive camp's impulsive 'go' and the conservative camp's fearful 'no-go' cannot lead to long-term stable profits. My balanced strategy is: **Set up your rifle and trap (place limit orders at 33-31 yuan), wait for the prey (price pullback) to fall into your ambush, and then capture it firmly with a solid net (5% position and 34 yuan stop-loss).** If the price does not pull back and rallies directly, then I congratulate the aggressive camp—I accept the loss, acknowledging I missed this opportunity, but I did not take the risk at the high. If the price pulls back and triggers my buy conditions, then I am in a more comfortable position with a more sustainable probability of success. Remember, solid long-term growth does not come from chasing highs and selling lows, but from accumulating one high-probability, disciplined, dynamically adjusted decision after another.

risk_management_decision

**Decision: Buy** As the chair of the Risk Management Committee, I have carefully weighed the arguments of the three analysts and the research manager's preliminary plan. The final ruling is that **Buy** is the current action with the best risk-reward self-consistency. This decision is not a complete endorsement of the aggressive faction but a prudent conclusion that deeply integrates the research manager’s phased position-building strategy with the neutral faction’s disciplined entry principles. ### I. Why not Sell? A sell requires evidence of fundamental deterioration, overvaluation, or identifiable downside risk. However, all attacks from the bearish side focus on “ancillary issues” and fail to undermine the core logic: - **Fundamentals have not deteriorated**: New orders grew over 30% year-over-year, and small-molecule CDMO surged over 50%—these are irreversible accomplished facts. Net profit attributable to the parent returned to positive growth, closing the channel for earnings decline. The safety analyst admitted, “New order growth is the only positive leading indicator.” - **Valuation is not in a bubble**: The current P/E of 40.1x falls in the middle of the reasonable valuation range of 36–45 CNY given in the fundamentals report. There is no systemic overvaluation. - **The strong technical trend has not reversed**: ADX is as high as 53.49, and +DI far exceeds –DI, indicating that bullish strength is fully dominant. Rejecting an entire trend structure based on short-term overbought signals contradicts the core conclusion of the technical analysis framework itself (“In a strong trend, the reliability of oscillator limit signals declines”). Therefore, Sell is rejected. ### II. Why not Hold? The hold option presupposes that the bull and bear arguments are truly balanced and that there is no directional catalyst. That is not the case currently: - **The quality of bull and bear arguments is not equal**: The bullish side has “order explosion”—an irreversible forward-looking data point—while the bearish side’s weapons are margin lag and technical overboughtness. When a leading indicator (orders) points strongly upward and negative indicators are merely derivatives of the main trend, it cannot be considered a draw. - **Directional catalysts are clear**: After the earnings pre-announcement, the market gave a confirmation signal with a trading volume of 4.47 ten-thousand lots (5 times the previous 5-day average) and a bullish candle with above-average volume exceeding 8%. This is not random volatility but a strategic repositioning of institutional capital at a fundamental inflection point. - **The neutral faction’s own contradiction**: Although the neutral analyst argues “don’t buy now,” the strategy is essentially “prepare to buy on a pullback,” which itself acknowledges the direction is up and is merely waiting for a better entry point. True holding should be based on an unclear direction, not on timing the wait. Therefore, the Hold option is also rejected. ### III. Why Buy—and How to Buy? The logic for buying is that the bullish evidence, on the whole, outweighs the bearish evidence, and remaining risks can be kept within an acceptable range through a precise plan. The research manager’s plan has already built an excellent framework. From a risk management perspective, I hereby confirm and refine it, especially incorporating reasonable warnings raised by the neutral and safety factions. **1. Risk Qualitative and Quantitative** - **Short-term overheating risk** (core concern of the safety faction): RSI 93.61, MFI 89.66, price deviation from the 5-day line by 21%—these are objectively extreme readings. The neutral faction’s note that “price already partially reflects the good news” is also noteworthy. However, this risk can be fully managed through **phased position building** and **entry discipline** without resorting to a “zero position” to avoid it. - **Margin risk** (common concern of the safety and neutral factions): The suspicion of “exchanging price for volume” requires us to verify margin improvement in subsequent quarters. This risk has been incorporated into the dynamic holding logic rather than used to veto the entire trade. - **Trend exhaustion uncertainty**: The aggressive faction uses ADX to assert trend continuation, but ADX does not provide information on the remaining space in the trend. We acknowledge this and therefore adopt **dynamic stop-loss and position-add conditions** rather than a one-time heavy position. **2. Refined Trader Plan** Building on the research manager’s proposal, I incorporate the neutral faction’s moving-average entry discipline and a tighter dynamic stop-loss system to create an implementation framework that balances “avoiding missing the move” and “avoiding chasing highs”: - **Establish base position (execute immediately)**: Maintain the research manager’s 2% of total portfolio assets as a base position, buying near 40 CNY. The significance is to prevent completely missing out—being fully in cash waiting for a pullback within a strong trend is itself a risk (the risk of missing the move), as the aggressive faction rightly noted. With an extremely low 2% base position, even if an extreme drawdown of 30% occurs, the portfolio’s net loss is limited to under 60 basis points, which is fully acceptable. - **Core addition (strict discipline)**: Stay closely aligned with the neutral faction’s “limit order hunting.” **Never add positions by chasing highs.** The first addition level is set between the 5-day line and the 10-day line, i.e., the 33.25–31.63 CNY zone, bringing the position to 4%–5% of the total portfolio. If the price does not pull back and continues rising, we do not chase further; the base position is enough to ride the trend, avoiding passive floating losses at high levels. If a deep pullback reaches the 20-day moving average at 28.24 CNY, that can be an extreme addition level, but we must assess whether fundamentals have weakened at that point. - **Stop-loss adjustment (incorporating neutral faction’s advice)**: The research manager’s full-position stop-loss is set at 27.40 CNY (below the 20-day moving average by 3%), which gives the trend considerable margin for error and is logically sound. However, to prevent the “boiling frog” syndrome of long-term holding losses, I introduce a **dynamic tracking mechanism**: if the price after addition breaks below the MA10 (31.63 CNY) and a death cross (MA5 crossing below MA10) occurs, we will unconditionally reduce the position back to the 2% base, releasing profits and risk. The final hard stop-loss remains at 27.40 CNY, ensuring an exit if the trend completely reverses. This adjustment absorbs the neutral faction’s thinking of using margin improvement as a holding condition but transforms it into observable, executable technical rules, avoiding the trap of earnings-report lag. - **Holding logic and exit criteria**: The core catalyst for buying is “explosion of new orders.” The condition for continuing to hold must evolve into “marginal improvement in margins” or at least “revenue growth not slowing.” If the next earnings report shows persistent margin deterioration with no signs of improvement (two consecutive quarters of “revenue growth without profit growth”), we should start reducing and eventually close the position, regardless of the stock price. This is the most direct response to the safety faction’s “Davis double kill” risk—not waiting for the risk to happen, but presetting unconditional exit triggers. **3. Target Prices and Scenario Analysis (in agreement with the research manager)** - **Conservative scenario**: Short-term overbought digestion, price returning to the 5-day to 10-day range (33–38 CNY), providing a window to add positions. - **Base scenario**: Strong trend continues, moving toward the upper end of fair valuation—target 42 CNY in 1 months, target 45 CNY in 3 months. - **Optimistic scenario**: Eli Lilly’s weight-loss drug catalyst materializes, margins show marginal improvement, pushing the P/E to the upper end of the industry average—target 50 CNY in 6 months. **4. Learning from Past Mistakes** The two types of mistakes the portfolio manager reminded us of at the end of the plan—being scared off by technical indicators and missing the move, and chasing highs to full position during euphoria—are precisely the epitome of this debate. The aggressive faction represents the correction after the previous missed move; the safety faction represents the trauma of being trapped after chasing highs. Our decision must avoid repeating either extreme. The **small base position + adding on moving average pullback + dynamic technical take-profit and stop-loss** adopted here is the specific answer designed for these two errors: the base position eliminates the fear of missing out, disciplined addition curbs the impulse to chase, and executable technical rules replace subjective guesses. **5. Comparison with the Research Manager’s Decision (Consistent, but Refined)** My risk assessment ultimately confirms the research manager’s “Buy” judgment but with key fine-tuning in execution: - The research manager correctly identified “cannot chase and add heavy positions” and creatively used a 2% base position with phased addition. I fully endorse this framework. - At the same time, I supplemented it with the neutral faction’s proposed “dynamic stop-loss and reduction conditions,” transforming the ex-post risk of “margin improvement next quarter” into an ex-ante technical tracking rule (reduce position if MA10 is broken), making risk management more timely and actionable, compensating for the potential lag inherent in relying solely on earnings report nodes. - The research manager’s logic for rejecting the safety faction’s “Hold” option (asymmetry in the quality of bull/bear arguments) is fully valid, and I adopt it. The safety faction’s zero-position suggestion essentially prioritizes “avoiding short-term pullback” over “capturing medium-term trend gains,” whereas our risk management solution demonstrates that with an extremely light base position and strict discipline, both can be achieved. In summary, at the current moment, it is recommended to take **Buy** action and strictly execute according to the refined plan above. The core principle is: **Use positions to manage uncertainty, not avoid uncertainty by staying in cash.**